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Resumo 
 
 
A aplicação da metabolómica com o intuito de revelar biomarcadores de eficácia 
ou toxicidade, assim como de fornecer uma compreensão bioquímica de 
mecanismos de ação, tem ganho maior interesse na comunidade científica. 
Neste trabalho os efeitos das nanopartículas de seda no metabolismo de 
macrófagos, que são um tipo celular importante no que diz respeito à 
incorporação de nanopartículas, foram investigados por metabolómica de 
espectroscopia de Ressonância Magnética Nuclear (RMN). Inicialmente, 
espectroscopia de RMN 1D e 2D foi aplicada para determinar a composição 
metabólica de macrófagos de rato (linha celular RAW 264.7), através da análise 
de extratos aquosos e lipídicos. Cerca de quarenta metabolitos foram 
identificados, estabelecendo uma base de dados dos metabolitos de 
macrófagos de rato. De seguida, esses macrófagos foram expostos a duas 
concentrações de nanopartículas de seda (10 e 500 µg/mL), selecionadas com 
base nos dados citotoxicológicos recolhidos previamente a este trabalho, e o 
seu impacto no metabolismo foi averiguado usando a mesma metodologia. 
Análise multivariada foi aplicada aos espectros de 1H RMN 1D de forma a 
investigar as alterações na composição dos macrófagos durante a exposição às 
nanopartículas de seda (SNPs). A concentração baixa de SNPs induziu poucas 
alterações no metaboloma celular comparativamente à concentração alta de 
SNPs, que resultou em alterações bioquímicas no metabolismo energético e 
ciclo do ácido cítrico, distúrbios no metabolismo de aminoácidos e modificações 
na membrana celular. Algumas variações foram comuns a todos os períodos de 
exposição, tais como o aumento dos aminoácidos de cadeia ramificada, lactato 
e tirosina, e a diminuição de glutamina, taurina, myo-inositol e ATP/ADP, 
enquanto que outras se revelaram ser mais específicas em relação ao tempo de 
exposição. As flutuações dependentes do tempo foram também visíveis nos 
lípidos, onde o colesterol, ésteres de colesterol e esfingomielina se encontraram 
mais elevados nas amostras expostas à concentração elevada de SNPs, 
enquanto que os ácidos gordos insaturados, plasmalogénio e fosfatidilcolina 
estavam mais elevados nos controlos. 
Estes resultados demonstraram que a aplicação de metabolómica de RMN para 
avaliar o desempenho de nanofármacos pode ser uma ferramenta importante 
para melhorar a nossa compreensão das interações célula-nanomaterial e os 
mecanismos subjacentes à toxicidade observada. 
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Abstract 
 
The use of metabolomics to reveal response markers of efficacy or toxicity, as 
well as to provide biochemical insight into mechanisms of action has gained 
increasing interest in the research community. In this work, the effects of silk 
nanoparticles on the metabolism of macrophages, which are an important cell 
type in regard to NP uptake, was addressed through Nuclear Magnetic 
Resonance (NMR) spectroscopy metabolomics. Firstly, 1D and 2D NMR 
spectroscopy was applied to determine the metabolic composition of murine 
macrophages (RAW 264.7 cell line), through the analysis of both aqueous and 
lipid extracts. Almost forty metabolites were identified, establishing a database 
of metabolites of murine macrophages. Afterwards, murine macrophages were 
exposed to two concentrations of silk nanoparticles (10 and 500 µg/mL), selected 
based on cytotoxicity data collected previously to this work, and the impact on 
their metabolic composition was assessed. Multivariate analysis was applied to 
the 1D 1H NMR spectra in order to search the compositional changes in 
macrophages during silk nanoparticles’ (SNPs) exposure. It was found that the 
low concentration SNPs induced few changes in the cells metabolome compared 
to the high concentration SNPs, which resulted in biochemical changes related 
to energy metabolism and TCA cycle, disturbance of amino acids metabolism 
and cell membrane modification. Some variations were common to all exposure 
periods, such as the increase in branched chain amino acids, lactate and tyrosine 
and the decrease in glutamine, taurine, myo-inositol and ATP/ADP, whereas 
other variations seemed to be more time-specific. The time-dependent 
fluctuations were also visible in lipids, where cholesterol, cholesterol esters and 
sphingomyelin were found to be relatively higher in SNP-exposed samples, while 
unsaturated fatty acids, plasmalogen and phosphatidylcholine were higher in 
controls. 
These results have shown that the use of NMR metabolomics to evaluate a 
nanomedicine performance may be a powerful tool to improve our understanding 
of cell-nanomaterial interactions and of the mechanisms underlying observed 
toxicities. 
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1.1. Introducing nanomedicine 
1.1.1. General overview 
Nowadays, the application of nanomaterials to therapy and diagnostic ends is one of the 
fastest growing areas in nanotechnology (1,2). Nanomedicine is a field of science which 
aims at improving diagnosis and treatment of life-threatening and debilitating diseases for 
which there are currently no adequate therapies (1–3). The definition of nanomedicine was 
achieved via consensus conference by the European Science Foundation’s (ESF) Forward 
Look Nanomedicine in the following way: “Nanomedicine is the science and technology of 
diagnosing, treating and preventing disease and traumatic injury, of relieving pain, and of 
preserving and improving human health, using molecular tools and molecular knowledge of 
the human body.”(4) 
The main areas of research and development of nanomedicine being developed for 
healthcare applications encompass (1,2):   
a) Diagnostics, devices/biosensors, and surgical tools used outside the patient; 
b) Nanostructured biomaterials (often combined with cell therapy) for biomedical 
applications, such as oral, parental, pulmonary, surgical implantation, or tissue 
regeneration; 
c) Nanopharmaceuticals (nanomedicines) and nanoimaging agents for patient 
administration, with diagnostic or therapy purposes. 
Nanomedicines are nanometre size scale complex systems, consisting of at least two 
components, one of which is the active ingredient, and being developed either as drug 
delivery systems or biologically active drug products. They are carefully engineered with 
innovative methodologies for physicochemical and biological characterization to ensure 
optimization of properties relevant to the clinical setting (5,6).  
Nanomaterials used as drug delivery systems or imaging agents are generally below 100 
nm in size in at least one dimension and may be constructed from a wide range of organic 
and inorganic materials. They include liposomal and lipidic complexes, antibody-based drug 
conjugates, polymer therapeutics, and nanoparticles. Figure 1 schematically shows these and 
other classes of nanomedicines. Each nano-sized construct can have different dimensions 
and a different surface composition, each class of nanomedicines displaying typical size 
ranges in the nanoscale (1,3).  
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The first drug delivery systems are now called 1st generation nanomedicines, and have 
already entered routine clinical use.  
There are several reasons for the rational design and development of nanomedicines: they 
can potentially improve transport of drugs across both external biological barriers (e.g. 
gastrointestinal (GI) tract and lung) or internal barriers (e.g. blood brain barrier); improve 
drug solubilisation and protection from metabolism; improve disease-specific targeting 
and/or controlled release (1–3). The encapsulation of drugs can also protect them against 
degradation by the body’s defence system, thus providing stability in systemic circulation. 
Nanocarriers may release drugs with varying kinetics, based on their ability to respond to 
physically stimuli (e.g. temperature, electric or magnetic field, light and ultrasounds), 
chemical stimuli (pH, ionic, and redox status), or biological stimuli (e.g. enzymes and 
inflammation). This provides an additional tool for controlling release kinetics besides 
diffusion and matrix degradation. Thus, the need of combining enhanced site specificity and 
local controlled release of the bioactive agent has encouraged the development of 
nanoparticles as nanomedicines (7,8). 
Encapsulating active ingredients into nanocarriers has allowed maximising therapeutic 
efficacy and patient convenience, because the pharmacokinetic (PK) profile could be 
improved compared to small molecule drugs. While small drugs distribute evenly throughout 
the body, resulting in a large volume of distribution (Vd), nanocarriers can take advantage of 
the enhanced permeability and retention (EPR) effect of leaky vasculature often observed in 
Figure 1 - Schematic representation of different nanomedicines under development. The nanomedicines 
models are not drawn to scale. Based on (2). 
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tumour and inflamed tissue. Tumour vasculature is typically comprised of poorly aligned 
endothelial cells with wide fenestrations (larger than 100 nm in size), and tumour tissue lacks 
functional lymphatics, resulting in preferred accumulation of nanocarriers in these tissues 
over healthy ones. Thus, the EPR effect leads to altered biodistribution, where the nano-
sized drug shows selective tumour accumulation thereby reducing Vd and improving target 
specificity of the treatment. Hence, the combination of reduced toxicity and superior 
therapeutic effect greatly improves the therapeutic window (9,10). 
An additional advantage of using nanocarriers is the possibility to achieve active targeting 
by attaching specific ligands to their surface, which interact with complementary cell 
receptors known to be overexpressed at the target tissue. The envisaged result is increased 
efficacy and reduced systemic toxicity due to accelerated clearance by the mononuclear 
phagocyte system (MPS) (3). Furthermore, while small molecular weight drugs can normally 
access the cell by diffusion across the plasma membrane and be effectively effluxed, the 
endocytic uptake of NPs can overcome drug resistance mechanisms (10). 
The recognition and uptake of nanoparticles by the body can be made by non-phagocytic 
eukaryotic cells, macrophages and dendritic cells. When the body recognizes NPs as foreign 
substances, the reticulum-endothelial system – now called the mononuclear phagocyte 
system (MPS) –, eliminates them from the bloodstream and the uptake occurs in the liver or 
the spleen. Moreover, opsonisation of the NPs may also occur in the bloodstream, in order 
to make the foreign substance visible to macrophages. In this way, particles attach to the 
macrophage surface through specific receptor-ligand interactions. To overcome these 
limitations, surface modifications such as altering the NP charge permits targeting and 
selective cellular binding (11,12).  
Currently, modern nanomedicines fit into three groups of emerging nanotechnologies: the 
first group consists of 1st generation nanomedicines that already entered routine clinical use 
(Table I). The second group encompasses nanomedicines being proposed for or currently 
undergoing clinical development for treating several diseases, manly cancer, and their 
clinical safety and efficacy status are already beginning to emerge. Finally, the third group 
includes putative nanomedicines based on novel nanomaterials: fullerenes, and carbon 
nanotubes, inorganic nanoparticles (e.g. gold, silver, quantum dots, silica and core shell 
silica-based nanoparticles), and natural and synthetic polymer-based nanoparticles, 
nanocapsules, and other sell-assembling nanostructures, and complex nano-architectures 
                                                                                    Chapter 1 - Introduction 
   5 
 
manufactured via new routes by innovative methods (1,2). Of these, only few are near to 
realising a clinical candidate and exhaustive pre-clinical testing is still needed. 
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Table I –  Main classes of nanomedicines already in the market or under clinical development, adapted from (1). 
 CLASS 
TYPICAL 
SIZE (NM) 
TYPICAL 
ADMINISTRATI
ON ROUTE 
USE 
PRODUCT 
EXAMPLES 
PRODUCTS 
APPROVED 
FOR THE 
MARKET 
Coated iron colloidals 10-100 i.v. (intravenous) 
Anaemia 
MRI imaging agents 
Feridex, 
Venofer 
Liposomes and lipidic drug carriers 
60-80 nm - > 1 
μM aggregates 
i.v. 
Cancer 
Opportunistic infections 
Doxil/Caelix 
Ambissome, Ablecet 
Drug nanocrystals 50–1000 oral 
Immunosuppressive 
Anti-emetic 
Rapamune, Emend 
Antibody targeted radiotherapy < 20 i.v. Cancer Zevalin, Bexxar 
Antibody-drug conjugate < 20 i.v. Cancer Adcetris, Kadcyla 
Nanoparticles  i.v. Cancer Abraxame 
Polymer therapeutics 
 Polymeric drugs and 
sequestrants 
 Polymer protein conjugates 
NA 
 
10-20 
i.m. (intramuscular), 
oral 
 
 
Multiple sclerosis 
Renal failure, diabetes 
 
Cancer, infectious diseases 
Copaxone´ 
Renagel, Welchol 
 
Neulasta, PEGasys 
PRODUCTS 
IN 
CLINICAL 
DEVELOP
MENT 
Polymer therapeutics 
 Polymeric-drugs conjugates 
 Block co-polymer micelles 
 Sell assembled polymer 
conjugate nanoparticles 
5-20 
 
20-100 
70 
i.v., oral 
 
i.v. 
i.v. 
Cancer  
Cancer siRNA delivery 
Opaxio, Prolindac 
NK150, SP1049 
 
CALAA01 
Liposomal combination therapy  i.v. Cancer CPX-351 
Hollow gold nanoparticles 150 i.v. Cancer Aurolase 
Silica nanoparticles  i.v Cancer  
Iron oxide nanoparticles  i.t. (intra-tumoral) Cancer (thermal ablation) Nanoderm 
Silver nanoparticles  topical 
Anticancer/  
Dermatitis 
Nucryst 
Hafnium oxide crystals  i.t. Cancer (radiotherapy) NBTXR3 
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1.1.2. Silk nanoparticles as emerging nanomedicines 
Silk is a biologically derived protein-based fibre-forming material spun by some 
Arachnida and Lepidoptera larvae such as silkworms, spiders, scorpion, mites and flies 
(13,14). Natural silk fibre consists of two types of proteins: silk fibroin (commonly referred 
as silk) and sericins. Sericins in association with silk fibroin have been shown to cause an 
inflammatory response, due to upregulated immunoglobulins (IgEs), thus they are usually 
removed for medical applications (15).  One of the most common forms of silk is obtained 
from the silkworm Bombyx mori, with typical molecular weights between 200 and 400 kDa. 
In fact, B. mori silk is the most commonly used in biomedical applications, including drug 
delivery, as compared to spider, since they are easier to domesticate and to harvest silk. In 
general, to prepare B. mori silk, the cocoons are boiled in an aqueous alkaline solution (most 
commonly sodium carbonate) to remove sericin from the silk fibroin (degumming) and the 
native protein is then fragmented, leading to a lower molecular weight silk (16,17). Silk 
fibroin contains large internal repeats, the amino acid composition of which consists of a 
sequence of six residues (Gly-Ala-Gly-Ala-Gly-Ser)n, which lead to the formation of rigid 
anti-parallel β-sheet structures due to the dominance of hydrophobic domains. These 
structures confer the strength, flexibility and resiliency associated to silk fibres (14,18).  
The ancient use of silk as a suture material, together with its known minimal adverse 
effects, has led to the recent approval of this fibre for medical applications by the Food and 
Drug Administration (FDA), for example as a surgical mesh (16). Also, silk fibres are 
considered promising materials for other biomedical applications, including drug delivery, 
due to their good biocompatibility, slow degradability and versatility to generate various 
materials formats such as films, gels, fibres, scaffolds and micro- or nanoparticles (13,19). 
Additionally, silk is less inflammatory than other common biodegradable polymers such as 
poly(lactide) (13,16). 
One of the advantages of silk, that makes it potentially suitable for drug-delivery 
applications, is that it is typically processed into an aqueous solution (referred to as 
regenerated silk) by disrupting the hydrogen bonding of the degummed silk fibres through 
the use of chaotropic agents and elevated temperatures (Figure 2) (10,14,20). These mild 
processing conditions, without the use of organic solvents or harsh environmental conditions 
and chemical modifications, favour the development of silk beyond its traditional use as a 
suture material. Several different material morphologies can be formed from natural silk 
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fibre for utilization in biomaterials. Regenerated silk fibroin solution can be processed into 
porous silk sponges, silk films, micro- or nanoscale coatings, hydrogels and micro- and 
nanoparticles (14,19). Additionally, the material properties of silk fibroin biomaterials can 
be tightly controlled during processing and fabrication, resulting in a broad range of silk-
based systems available for medical applications (16). 
As for other natural polymers, an additional advantageous aspect of silk is that it may be 
metabolized in vivo by digestive enzymes into peptides and amino acids (13). Indeed, even 
though silk degradation and excretion from the body remain to be established, enzymatic 
degradation, as part of the foreign body response, and further clearance by macrophages, 
appear to be the most viable route for in vivo biodegradation (10). The rate and behaviour of 
the degradation of silk by proteases is dependent on many factors, including silk processing 
and material properties (morphology, molecular mass and crystallinity/β-sheet content), and 
mechanical and biological conditions at the site of implantation (14,16). Several types of 
proteases are being studied, including α-chymotrypsin and collagenases, which catalyse 
Figure 2 - Silk fibroin preparation. Bombyx mori cocoons are purified from sericin by means of boiling in an 
alkaline solution. Degummed silk fibroin can be processed into fibre biomaterials including sutures, meshes, 
woven fabrics, yarns and ropes. To prepare aqueous silk solution, degummed silk fibroin is dissolved in salt 
and then the salt is removed with dialysis. The aqueous silk solution can then be processed into various 
material formats for drug delivery. Adapted from (16). 
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hydrolysis reactions and contribute to silk biodegradation in peptide fragments and amino 
acids that can be readily metabolized and excreted (14). While chymotrypsin is a mammalian 
enzyme, synthesized in the pancreas and excreted from there, and consequently accumulated 
in the duodenum of the gastrointestinal tract, protease type XIV is not. Thus, protease XIV 
does not reflect degradation properties in vivo, which need to be determined empirically. 
Both enzymes have been used to compare the degradation properties and to understand the 
enzymatic degradation kinetic of different silk formulations, but only the first one is able to 
reflect the in vivo behaviour and overall tolerance (20,21).  
A few studies have examined the ability of silk to entrap and release (model) drugs, 
showing that silk-based biomaterials are able to stabilize the payload and control drug release 
using endogenous parameters such as crystallinity and molecular weight of the silk fibroin. 
Drugs are typically incorporated by mixing the drug with the silk solution either before 
material production or after the formation of the drug delivery system (by surface decoration 
with the drug or by means of either chemical coupling or adsorption). Native silk has the 
ability to strongly absorb low molecular weight drugs, the overall loading efficiency being 
dependent on the drug net charge and its correlation with silk’s isoelectric point (10,16). The 
release characteristics have been found to be governed either by diffusion of the payload 
from the carrier or by solubilisation and/or degradation of the silk. For example, when 
casting a thin silk film, the dried fibroin (also referred as silk I) was found to be completely 
water soluble and, therefore, the drug payload was released in accordance with the 
solubilisation characteristics of the film in aqueous environment (10). Silk I could also be 
easily converted into a stabilized silk II form (richer in β–sheets) through a gentle process 
where water is removed from the hydrophobic domains, permitting tight packing of these β–
sheets (14,20). Importantly, the manipulation of silk crystallinity has been found to provide 
control over the release of doxorubicin (a clinically relevant chemotherapeutic agent), thus 
potentially allowing systemic and local adverse effects to be minimised while maximising 
therapeutic efficacy (21). Moreover, inducing crystallinity in silk makes it more compatible 
with a wide range of payloads, including proteins (22). 
Several silk formats have already been tested as drug delivery systems, taking into 
account the multitude of factors that govern the final design of the system (10). Silk films 
have been used for promoting long-term adenosine release from adenosine kinase deficient 
embryonic stem cells. This study has demonstrated that silk fibroin constitutes a suitable 
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material for the directed differentiation of embryonic stem cells and for cell-mediated 
therapeutic release of adenosine. Therefore, silk films decorated with bioactive molecules 
could be used for local drug delivery via direct implantation (15). Also, Seib’s team revealed 
that doxorubicin-loaded silk films could directly be applied to mice using a humanised 
orthotropic breast cancer model (adenocarcinoma). By manipulating silk mechanical 
properties, the release of doxorubicin could be controlled, which minimised systemic and 
local adverse effects, while maximising therapeutic impact (21). 
Regarding silk hydrogels, they have been combined with osteoblasts-like cells and 
injected in critical-size femur defects in rabbits. This resulted in greater trabecular bone 
volume and thickness, with significant higher mineral and rate of bone formation (14). In 
another study, self-assembling silk hydrogels were loaded with doxorubicin and further 
injected in tumours of mice. Reducing primary tumour growth and metastatic spread, silk 
hydrogels were found to be well suited for the local delivery of chemotherapy of breast 
cancer (22). 
In the case of silk microspheres, when they were loaded with horseradish peroxidase 
(HRP), a model drug, they showed controlled and sustained release of action for 10 to 15 
days (23). Moreover, a silk/polymeric scaffold system also showed high encapsulation 
efficiencies and good control over the feature sizes which allowed a slow release of Bone 
Morphogenetic Proteins (BMPs) during 14 days (15).  
Silk nanoparticles (SNPs) are also being designed as new drug nanocarriers. 
Nanoparticles provide advantages over the administration of free drugs and other silk-based 
biomaterials since they can overcome drug resistance mechanisms, decrease side-effects, 
enhance drug bioavailability and have a higher intracellular uptake compared to 
microparticles, for example. Moreover, they can be easily transported via the circulation to 
various body sites, thus improving medical treatments (10,18). Some studies involving silk 
nanoparticles as drug delivery systems were performed. Zhao’s team has investigated the 
controlled release properties of SNPs containing indomethacin (a non-steroidal anti-
inflammatory drug). It was demonstrated that SNPs may sustain the indomethacin release 
and these nanoparticles can be used effectively as a drug carrier (18). SNPs were also tested 
in the cytosol of murine squamous cell carcinoma cells. The growth factor release from the 
nanoparticles showed significantly sustained release over 3 weeks, implying potential 
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application as a growth factor delivery system, without significant changes regarding 
toxicity (24).  
Additionally, SNPs were also prepared for anticancer drug delivery. Using magnetic 
SNPs loaded with doxorubicin, Tian et al. studied the magnetic-guided drug delivery in a 
humanized orthotropic breast cancer model and chemotherapy performance of drug-resistant 
cancer. These SNPs have demonstrated the ability of magnetic targeting in vivo and effective 
chemotherapy, working well as a novel drug delivery system in cancer therapy (25). In 
another study, biological derived-silk based nanoparticles containing curcumin showed a 
higher efficiency against breast cancer cells and have potential to treat in-vivo breast tumours 
by local, sustained, and long-term therapeutic delivery (26). For focal therapy of breast 
cancer, Seib et al. demonstrated the potential of silk to serve as a stimulus-responsive 
nanomedicine, with overall negative surface charge and pH-dependent release. Hence, SNPs 
loaded with doxorubicin were able to serve as a lysosomotropic delivery platform and 
overcome drug-resistance mechanisms in vitro (19). In addition, the pH-sensitivity of the 
nanoparticles is effective for drug delivery systems application because of the difference 
between the extracellular pH of normal tissue (pH 7.2-7.4) and of many solid tumours (pH 
6.2-6.9) (7). 
In parallel with the development of nanoparticles from Bombix mori silk, recombinant 
spider silks have been engineered for use in non-viral gene and siRNA delivery. Silk 
sequence was modified to control self-assembling of β-sheets structures in silk, but also cell-
binding domains were included to enhance cell adhesion. The most widely studied spider 
silk in terms of variants is dragline silk from the spider Nephila clavipes. These recombinant 
silk-like polymers can be tailored to further control targeting, size, stability and related needs 
for gene delivery. In these studies, silk was prepared in the form of microcapsules, 
microspheres and polyioncomplexes (15). 
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1.2. Safety issues and toxicity assessment of emerging nanomedicines 
1.2.1. General remarks 
For emerging nanomedicines, inspired on 1st generation products or based on novel 
nanomaterials, to progress towards clinical application, they must undergo a rigorous safety 
assessment, in order to estimate the risk-benefit in relation to a specific proposed clinical 
use. For that purpose, it is  essential to establish the toxicity profile of each nanomedicine 
being developed, as well as to understand its mode of action and how its physicochemical 
properties influence both toxicity and efficacy (1,2). 
This task is often complicated, especially given that many variables may modulate the 
biological responses, including the size and surface chemistry of the nanoconstruct, the 
nature of the bioactive payload, the linking chemistry used between components, or the 
degradation of particular components into secondary products (1,27). Whereas size and 
shape play a role in how the materials are distributed and eliminated of the body, affecting 
the mode of endocytosis, cellular uptake and the efficiency of particle processing in 
metabolic pathways, chemical composition at the surface of nanomedicines will mostly 
define their chemical interactions, because the surface is in direct contact with the body 
membranes (27). Generally, the pharmacokinetics, body distribution, nanomedicine 
stability, and the metabolic fate of all components impact on the overall toxicological profile 
observed (1). 
Therefore, it is very important that the toxicological profile of a nanomedicine is 
evaluated in its entirety. However, at early development stages, the preliminary safety 
assessment of individual components (envisaged for incorporation into a nanomedicine) may 
also play a critical role in the design of the overall construct (1,2). Figure 3 summarizes some 
of the tests that are typically used to assess the safety of component nanomaterials or the 
whole nanomedicine. 
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A first important issue in nanotoxicology is that the nanomaterials to be tested in a 
biological system (either in vitro or in vivo) are thoroughly characterized, so that meaningful, 
reproducible results are ensured. Nanoparticle analysis should involve purity certification, 
controlled morphology, polydispersity and solubility, conductivity or redox behaviour, 
among others, to provide reliable results on physical-chemical states and on stability. 
Typically, multiple measurement techniques must be adopted and applied to complex 
nanomaterial systems to accomplish validity since no single analysis can provide sufficient 
information to correlate nanoparticle characteristics with biological response (27–29). 
Biological testing of a nanomedicine or its components should then involve in vitro and/or 
in vivo testing. In vitro cellular tests are the most common assessment method used to 
understand the mechanisms of cell damage, including triggering of apoptosis and oxidative 
stress (cytotoxicity). These tests are easier to control and reproduce and less expensive than 
animal studies. Also, they provide a rapid and effective means to assess nanomedicines for 
a number of toxicology endpoints (24,26,27). Controlling the experimental conditions such 
as temperature, pH, nutrient and waste concentration, as well as the nanomedicines 
concentration, assures that the measured cell death corresponds to the toxicity of the added 
nanomedicines and not to the unstable culture conditions (30). Furthermore, in vitro assays 
Figure 3 - Typical panel of tests used to define the preliminary safety of a nanomaterial (left) that is a candidate 
for incorporation into a nanomedicine, and the safety and efficacy of a nanomedicine (right). Adapted from 
(1). 
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allow to use various cell lines, mimicking different tissue environments, and reactive 
pathological or inflammatory conditions likely observed in vivo (12,28,31). 
Several techniques can be used to assess the in vitro toxicity of nanomaterials, such as: 
assays for cell viability or proliferation; mechanistic assays (ROS generation, apoptosis, 
necrosis and DNA damaging potential); microscopic evaluation of intracellular localisation 
(comprising techniques like SEM-EDS, TEM, AFM, Fluorescence spectroscopy, MRI and 
VEDIC microscopy); gene expression analysis; in vitro hemolysis; and genotoxicity (31).  
Following combined results from in vitro cellular assays, nanotoxicity studies may be 
complemented with in vivo experiments to achieve validation and progress towards clinical 
development. In vivo experiments can potentially provide information on both the 
pharmacokinetics (i.e. the fate of the administered substance, including its absorption, 
distribution, metabolism and excretion), and pharmacodynamics (i.e. the effects caused on 
the organism). Hence, in vivo pharmacokinetics and pharmacodynamics studies are an 
essential part of nanomedicine evaluation and design (23,28).  
Regarding the mechanisms by which nanomaterials exert toxic effects, one of the main 
reported pathways is the generation of reactive oxygen species (ROS) and mitochondrial 
stress. ROS formation is also interconnected with cytoskeleton disorganization or damage, 
decreasing actin dynamics and reducing mitochondrial membrane potential via open 
voltage-dependent anion channels. This increases mitochondrial ROS release and cell 
apoptosis sensitivity (12). The reduction of mitochondrial activity leads to a decrease in ATP 
production that is necessary for many cellular functions. Thus, screening for ROS in relation 
to the toxicity of nanomaterials is important since the production of ROS can result in 
inflammatory responses, apoptosis, necrosis, fibrosis, hypertrophy, metaplasia, and 
carcinogenesis (12,33,34).  
 
1.2.2. Toxicity of silk nanoparticles (SNPs) 
Regarding the safety of SNPs, little information is available. Silk derived from natural 
sources or obtained through recombinant engineering approaches has been increasingly used 
for biomedical applications. However, although different silk formats (e.g. films, scaffolds, 
sutures) have demonstrated good biocompatibility, these data cannot be extrapolated to 
assure the safety of SNPs proposed for systemic administration. In vitro and in vivo studies 
are needed to support the safe transfer of SNPs across all stages of development (10). 
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Some data of the SNPs internalization mechanisms suggest that endocytosis contributes 
to the uptake, trafficking rate and intracellular fate (2). In a study by Kundu et al., the 
nanoparticles internalization process was assessed by labelling the nanoparticles with FITC 
(fluorescence isothiocyanate) and observing the cellular uptake by confocal laser scanning 
microscopy (CLSM). The SNPs internalization occurred by endocytosis, and SNPs were 
mainly present in the perinuclear region, remaining viable and without causing any overt 
cytotoxicity (24). Following, Seib’s team examined SNPs intracellular fate by live confocal 
microscopy, confirming that SNPs enter the cells by endocytosis (19).  
The few studies which have investigated the cytotoxicity of SNPs through in vitro 
experiments suggested none or minimal toxicity. Human breast cell lines were shown to 
maintain their viability when exposed to SNPs of 35-120 nm diameter, at a concentration of 
100 µg/ml for up to 24 hours, as assessed by the MTT assay (24). Cell cycle analysis further 
revealed normal cell cycle distribution without any visible signs of cell cycle arrest (19,24). 
Despite these results, further information on how SNPs interact with different cell types is 
needed for characterizing and understanding the SNPs safety profile (19). 
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1.3. Metabolomics in nanomedicine/nanotoxicology 
1.3.1. The metabolomics approach 
The metabolome consists of the inventory of endogenous small molecules (with 
molecular mass lower than 1000 Da) present in a biological system as a result of 
intermediary cellular metabolism. Metabolomics (or metabonomics) is concerned with the 
comprehensive identification and quantification of metabolites in biological systems (cells, 
tissues, body fluids) and of their changes in response to pathophysiological stimuli or genetic 
modification (35,36). 
Since metabolites play a very important role in connecting the different pathways that 
operate within a living cell, metabolomic studies are an important part of integrated system’s 
biology approaches, used to study pathological processes or the effects induced by different 
external stimuli (e.g. drugs, nanomaterials) (37). Assessing the metabolic profiles or 
signatures potentially allows to estimate cellular function and the overall physiological status 
of an organism (38).  Indeed, many pathological conditions can be reflected by changes in 
metabolite levels, as shown by the increasing number of metabolomic studies in the field of 
disease diagnosis and monitoring. The most widely investigated classes of diseases include 
cancer, diabetes, cardiovascular and neurological diseases. Metabolomics technologies also 
have the potential to provide rapid screening for biomarkers of toxicity, showing great 
promise in drug toxicological assessment and development, as well as in the fields of 
nanotoxicology and nanomedicine (38). 
Several sample types with different complexity can be retrieved for metabolomics studies, 
from cell cultures to tissues and biofluids of animal models or human subjects (34,38). 
Nuclear Magnetic Resonance (NMR) spectroscopy and mass spectrometry (MS) (the latter 
being typically coupled to different chromatographic techniques, such as liquid or gas 
chromatography) are the most often employed methods for metabolome profiling. These 
techniques are the major tools to detect global changes in the metabolome because they allow 
a large number of metabolites to be detected simultaneously and non-selectively (34,39). 
Compared to MS, NMR is less sensitive, with detection limits in the sub-milimolar range, 
but it offers advantages in terms of high reproducibility and non-destructiveness (allowing 
sample recovery for further analysis). Moreover, it allows the direct analysis of cells, tissues 
and biofluids, with minimal sample interference, and it is quantitative in nature, providing a 
large amount of structural and quantitative information in a single record (34,38). As NMR 
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has been the technique used in this work, its basic principles will be briefly described in the 
following section. 
1.3.2. Basic principles of Nuclear Magnetic Resonance (NMR) Spectroscopy 
The nuclei of certain atoms possess an overall spin (I) different from zero, which makes 
them detectable by NMR. These nuclei include, for instance, the isotopes 1H, 13C, 31P, 15N 
(I = ½) and 2H, 14N (I = 1). The hydrogen isotope (1H) is the most commonly observed 
nucleus in NMR metabolomics due to its ubiquity in metabolites and high natural abundance 
(99.98 %) (40).  
The nuclear spin generates a magnetic dipole moment µ, which in the presence of an 
external magnetic field B0 aligns in a discrete number of orientations, corresponding to 
different energy levels. NMR spectroscopy is based on the transition between these energy 
levels (40,41). For nuclei with spin I = ½, like protons, there are two possible orientations, 
parallel and anti-parallel to B0, each characterized by a magnetic quantum number m and a 
different energy level (Figure 4). At the equilibrium state, there is an excess of nuclei at the 
lower energy level, but when an oscillating magnetic field B1 is applied, through a 
radiofrequency (RF) pulse, transition to the higher energy level occurs and the nuclei become 
excited. Once the RF pulse is turned off, the nuclei return back to equilibrium, through 
relaxation, and this process is recorded as a time domain signal called the free induction 
decay (FID). The FID is then transformed into a frequency domain spectrum through Fourier 
transform (FT) (41).  
Figure 4 - Schematic representation of the nuclear spin energy levels of a spin- ½ nucleus in a magnetic 
field. The energy difference between the two states is given by ΔE= γħB0, where ΔE is the energy difference 
between the two states, mI  the magnetic quantum number, ħ=h/2π (where h is Planck’s constant) and B0 
the magnetic field. Adapted from (41). 
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The different signals in the NMR spectrum of a molecule arise from the different 
electronic environments of the nuclei, because the bonding electrons create their own small 
magnetic field; thus, each proton (or group of equivalent protons) resonates at a specific 
frequency, giving rise to signals in different positions of the NMR scale. This scale is 
calibrated to the frequency of a reference compound (e.g. tetramethylsilane, TMS) and the 
frequency values are converted to parts per million (ppm). The resulting chemical shift scale 
(in ppm) is independent of B0, thus allowing chemical shifts obtained from different 
instruments to be compared (42). The 1H absorption regions of some characteristic functional 
groups are comprised within the narrow range of 0 – 14 ppm: saturated hydrocarbons 
generally absorb between 1.0 and 4.0 ppm, whereas the olefinic protons appear in the region 
of 5.0 – 6.5 ppm and the resonances of aromatic protons are in the region of 6.5 – 8.5 ppm 
(41). Figure 5 shows the typical 1H chemical shift ranges of some functional groups in 
organic compounds. 
Another characteristic feature of NMR signals is that they are often split into several lines 
due to nuclear spin-spin interactions mediated through the electrons of the chemical bonds, 
and known as scalar coupling. The multiplicity and magnitude of the splittings (coupling 
constants, J) provide knowledge about the number of neighbouring protons and their bond 
connectivities (40).  
Finally, it is also important to mention that signal area is proportional to the number of 
protons that originate the peak, hence, to compound concentration. Therefore NMR is 
inherently quantitative and it can be used for quantification purposes (40,43). 
 
Figure 5 - Typical 1H chemical shift ranges (in ppm) of some functional groups. Based on (41). 
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1.3.2.1. Main one- and two-dimensional NMR experiments in metabolomics 
The biological samples usually analysed in metabolomic studies (biofluids, tissues and 
cells) typically show complex profiles, comprising many overlapped signals, and a strong 
water signal which needs to be suppressed as it would otherwise dominate a large section of 
the spectrum and cause dynamic range problems (37). This is typically achieved by the 1D 
NOESY (nuclear Overhauser effect spectroscopy) pulse train with presaturation during 
relaxation delay and mixing time (standard water presaturation used in this work), the WET 
sequence (water suppression enhanced through T1 [spin lattice relaxation] effect) or the 
Watergate water suppression scheme (44). 
 To deal with spectral overlap and identify the metabolites present in complex biological 
samples, 2D NMR experiments are usually employed, as they allow increasing the signal 
dispersion and revealing molecular connectivities. The more commonly used 2D 
experiments include: correlation spectroscopy (COSY) and total correlation spectroscopy 
(TOCSY) experiments that provide spin-spin coupling connectivities (usually over 3-5 
bonds), giving information on which signals belong to the same spin system; J-resolved 
spectroscopy (JRES), that allows spectral simplification, minimizing overlap due to 
contributions of substances with short 1H spin-spin relaxation times (T2) and helping to 
determine coupling constants; and inverse-detected heteronuclear correlation methods such 
as heteronuclear single quantum correlation (HSQC), where signals correspond to 1H’s and 
13C’s directly bound. (41,45).  
 
1.3.3. Multivariate analysis: principles and tools 
After data acquisition and processing, metabolite signals are usually subjected to 
multivariate statistical analysis to detect consistent variation patterns (figure 6) (34). Indeed, 
since each spectrum comprises a wide range of variables (metabolites) and numerous spectra 
are often acquired within a study, multivariate analysis (MVA) is required to reduce data 
complexity and extract meaningful biochemical information. MVA usually involves the 
application of unsupervised methods such as Principal Component Analysis (PCA) and 
hierarchical cluster analysis (HCA), together with supervised methods such as Partial Least 
Squares – Discriminant Analysis (PLS-DA), where information about sample class is 
provided and class separation is maximized (34). 
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 Principal Component Analysis (PCA) and Hierarchical Cluster Analysis (HCA) are very 
useful for revealing grouping trends and outliers in a sample set. The idea behind PCA is to 
explain the original data variance in a lower dimensional space defined by Principal 
Components (PC’s), which are linear, uncorrelated combinations of the original variables 
(46). Through PCA, the original data matrix X is decomposed into a scores matrix (T), a 
loadings matrix (P) and a residuals matrix E (part of X that is not explained by the model), 
according to the following equation: X = TPt + E = t1p1
t + t2p2
t + E (where t denotes the 
transpose). The first PCA component (t1p1
t) contains the largest matrix variance, the second 
component the second largest variance, and so on, so that all components are mutually 
orthogonal to each other (47,48). 
Figure 6 – General overview of the typical strategy followed in metabolomics studies. Adapted from (95). 
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By projecting the observations (spectra) into the new PC-coordinate system, we obtain a 
scores plot (Figure 7), which allows visualizing the trend for samples to group together or to 
separate along one axis, according to their similarities or differences. Moreover, by plotting 
the corresponding loadings, we obtain information about the original variables that are 
responsible for the sample distribution observed in the scores plot.  
Hierarchical Cluster Analysis is an exploratory multivariate analysis method that allows 
the cluster structure of a dataset to be detected and the hierarchical relationship of the clusters 
to be revealed. This unsupervised approach enables samples to be grouped according to their 
dissimilarity or similarity, usually called distance, in the variable space. To unveil the 
clusters and trends, the distance matrix is calculated and an agglomerative clustering 
algorithm is performed. Based on that algorithm, a final dendrogram is constructed 
representing in which the closest clusters are most similar. Thus, this technique improves 
the understanding of the structure of the dataset, presenting visual information of the cluster 
structure (46,49,50). 
Unlike PCA and HCA, supervised methods like PLS-DA allow maximizing the 
separation between pre-defined classes (e.g. control/exposed, low/high dose, etc.), 
facilitating the interpretation of the differences between them (46,47). 
While PCA and HCA are methods that only consider the structure of the data matrix, X, 
PLS models the relationships between the data matrix X and a second matrix, Y, which can 
either contain quantitative (e.g. concentration of endogenous metabolites) or qualitative 
Figure 7 – Schematic representation of a principal component analysis model. Adapted from (47). 
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values (e.g. class membership). In the latter case, it is typically used in conjunction with 
discriminant analysis (PLS-DA), which is very useful in metabolomics studies aiming at 
differentiating sample classes.  
In PLS, the new variables (called latent variables, LVs) are calculated not only to model 
the variance in X (as in PCA) but also its correlation with Y, according to the following 
equations: 
X = TPt + E 
Y = TCt + F 
Where T is the matrix of the extracted scores (of both X and Y), P and C are the loadings 
matrices, and E and F the residuals of X and Y, respectively (37,51). The T scores are linear 
combinations of the original X variables and the weights (W) which define the quantitative 
relationship between X and Y.  
Similarly to PCA, the results of PLS-DA can be visualized through scores and loadings 
plots. Additionally, the loadings may be coloured as a function of variable importance in the 
projection (VIP) to highlight the most discriminant metabolites (those with VIP > 1).  
 
1.3.4. Univariate statistics 
In order to assess the statistical significance and magnitude of variations in individual 
metabolites, univariate statistics may be applied, complementary to MVA. Commonly used 
methods include the t-test, the Wilcoxon test (if data are not normally distributed), effect-
size estimation, and analysis of variance (ANOVA) (46,52). 
In the context of this thesis, the Shapiro-Wilk test was primarily performed in order to 
test for normality. For normally distributed data, the t-test was performed, while for 
nonparametric metabolites, the Wilcoxon test was used. These methods allowed to 
statistically evaluate the significance of the difference in average metabolite levels (53,54). 
The t-test is a standard statistical approach to examine if a study’s result is statistically 
significant through the null hypothesis (no difference between the means compared). For 
that purpose, the probability for the null hypothesis rejection (p-value) is determined at a 
pre-established significance level; typically, a difference between group means is considered 
statistically significant if the p-value is inferior to 0.05. However, the p-value does not 
provide crucial information about the magnitude of the variation of interest or its precision, 
besides being influenced by sample size (55). To deal with these limitations, another 
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statistical parameter, the effect size (d), has been increasingly used (56). This parameter, 
calculated according to the equations below (1 and 2), gives an indication of the magnitude 
of the variation, while accounting for the standard deviations (𝑠1 and 𝑠2) associated with the 
means compared (?̅?1 and ?̅?2) and the number of samples (𝑛1 and 𝑛2). Moreover, it is less 
sensitive to sample size, allowing increased confidence when comparing small sample sets. 
For the standardized mean differences between two groups, Cohen et al. (57) classified effect 
sizes as small (d = 0.2), medium (d = 0.5), and large (d ≥ 0.8). The 95 % confidence interval 
(CI) around the standardize mean differences is calculated according to equation 3 (55,56).  
 
𝑑 =  
?̅?1 −  ?̅?2 
𝑠
 
 
𝑠2 =  
(𝑛1 − 1) × 𝑠1
2 +  (𝑛2 − 1) × 𝑠2
2
(𝑛1 +  𝑛2) − 2
 
 
𝑑 ± 1.96 √
𝑛1 +  𝑛2
𝑛1𝑛2
+
𝑑2
2(𝑛1 +  𝑛2)
  
 
 
1.3.5. Metabolomics applications in nanomedicine/nanotoxicology: state-of-
the-art 
While metabolomics has been extensively applied in the fields of disease diagnosis or 
toxicology, the applications in nanomedicine/nanotoxicology are still scarce. In the next 
subsections, metabolomic studies of the impact of different NPs on either cellular or animal 
models will be reviewed. A list of those studies is summarised in Table II. To our knowledge, 
no studies on silk nanoparticles have been reported, this thesis constituting the first account 
on the subject.  
1.3.5.1. Silica (SiO2NPs) nanoparticles 
Silica nanoparticles (SiO2NPs) are increasingly used in the biomedical field, mainly due 
to their excellent solubility and high stability, and can enter biological systems through 
numerous routes. Despite their favourable biocompatibility, some investigations have 
revealed that silica NPs exposure exerts adverse effects such as cytotoxicity and oxidative 
Equation 1 
Equation 2 
Equation 3 
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stress (58–60). In addition, there have been reports of inflammatory responses, 
hepatotoxicity, and fibrosis following exposure (34). As shown in table II, a few studies have 
addressed the cellular and in vivo responses to SiO2NPs by metabolomics, using different 
analytical techniques (1H NMR spectroscopy, GC/MS and LC/MS). The cytotoxicity of the 
NPs was demonstrated by a significant metabolic shift between control and treated cells. In 
one of such studies, cell metabolic variations revealed to be dose-dependent, causing 
compositional changes related to membrane degradation, catabolism of carbohydrates and 
proteins, and oxidative stress response (60). In particular, the authors reported increases in 
some lipids, like triglyceride, LDL, VLDL, and in lactate/alanine ratio, together with 
decreases in several amino acids, ATP and other metabolites (60). In another study, after the 
treatment with SiO2NPs, cellular amino acids were down regulated and, on the contrary, urea 
was up regulated. Moroever, higher levels of lysophosphatidylcholine (LPC) and 
lysophosphatidylethanolamine (LPE), and decreased levels of reduced glutathione (GSH) 
were reported, based on LC/MS measurements.  LPC and LPE have been postulated to be 
biomarkers of biochemical injury arising from cellular toxicity (59). Another study with 
Kupffer cells (KC) indicated that SiO2NPs cause hyperplasia, hepatic inflammation, and 
oxidative stress, which lead to changes in the biochemical composition of the liver. After the 
exposure to SiO2NPs, KC released bioactive mediators, such as ROS, TNF-α, and NO, which 
subsequently contributes to hepatotoxicity (58). The significantly altered metabolites are 
involved in energy, amino acid, lipid and nucleotide metabolism, indicating impairment of 
the Krebs cycle and the occurrence of oxidative stress (34,58–60).  
The toxicological effects induced by SiO2NPs can drastically change based on particle 
formulation, size, shape and type. Metabolomic variations and compositional changes due 
to toxicological effects can provide much better understanding of SiO2NPs and their 
metabolic fate, offering a chance to better define the bio-safety of this biomaterial (60–62). 
1.3.5.2. Iron oxide nanoparticles 
Ultra-small superparamagnetic particles of iron oxide (USPIO) are excellent tools in the 
biomedical field since they can be functionalized for various applications and guided by an 
external magnetic source. These compounds have been developed as intravenous contrast 
agents for early detection of abnormal tumour associated lymph node and bone marrow, as 
well as contrast agent to improve magnetic resonance imaging (MRI) in vivo. In general, 
they are classified as biocompatible, showing no severe toxic effects in vitro or in vivo. 
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However, the potential biotoxicity and the disturbances of hepatic, renal and cardiac 
functions were derived from metabolomics data following USPIO administration (30,63,64). 
Feng and his colleagues have demonstrated varying effects of USPIO on the metabolic 
profile of different tissues including kidney, liver and spleen of rats, through High Resolution 
Magic Angle Spinning (HRMAS) 1H NMR.  An intravenous injection (tail vein) of coated-
USPIO was administrated to rats, and the harvested tissue samples reflected several effects 
in metabolic pathways including energy, lipid, glucose, and amino acids metabolism. The 
disturbance and impairment of biological function in these specific organs were dependent 
on the particles size and surface chemistry of USPIO (64). In another Feng’s study, 
metabolomic analysis revealed USPIO-induced metabolic changes in the blood of injected 
animals. Plasma samples showed a relative increase in intermediates of the Krebs cycle such 
as succinate and citrate, in glucose, and in the end-products of glycolysis such as lactate and 
acetate. USPIO administration also led to elevation of plasma inositol, choline and 
glycerophosphocholine. Similar changes in triglycerides and cholesterol were observed from 
clinical biochemistry and metabolomic analysis of NMR data derived from rat plasma. The 
metabolic changes in VLDL and HDL were suggested to be possibly related to USPIO-
induced renal failure and a risk factor for coronary heart disease (65). 
1.3.5.3. Gold and silver nanoparticles 
Gold and silver nanoparticles have received special attention since they have a great 
potential for applications in drug delivery systems, ultrasensitive chemical and biological 
sensors, as catalysts and in therapy (66).  
Generally, gold nanoparticles provide non-toxic routes to drug and gene delivery 
application, being able to deliver large biomolecules (peptides, proteins, or nucleic acids). 
Moreover, gold nanorods (Au NR) can be applied to amplify the biorecognition of anticancer 
drugs, emerging as one of the most promising putative anti-tumour treatments. Extensive 
research have been performed on the cytotoxicity, biocompatibility and biodistribution of 
several Au NR with different physicochemical properties like size, shape and surface group 
modifications (66,67). Zhang and his team have studied metabolic changes in tumour and 
normal cells after exposure to protein-coated Au NR, through 1H NMR. Their results showed 
time-dependent and cell-specific metabolic response of tumour cells and normal cells. 
Protein-coated Au NRs exposure modulated the micro-environment of cells by suppressing 
the levels of lactate, which might be vital for cancer growth, but also induced severe 
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oxidative stress and subsequent cell death in tumour cells whilst the normal ones survived. 
Normal cells had an overwhelming antioxidant capability as a result of activated glutathione 
synthesis and transformation into GSSG during the process of scavenging free radicals. This 
experiment provided important information in designing anti-cancer drugs to destroy only 
cancer cells and not normal and healthy cells. Moreover, metabolomics helped to elucidate 
molecular mechanisms of anti-cancer drugs action (67). 
Silver is used in consumer products as nanoparticles (Ag NPs) in refrigerators, 
toothpastes and health drinks. For that reason, it is important to understand the potential 
physiological, pharmacological and toxicological properties of silver. Ag NPs have 
displayed only minimal toxicity in animal studies and good biocompatibility, however, little 
information is available on the mechanism of action of silver nanoparticles in mammals 
(66,68). Hadrup’s team employed metabolomic investigation with HPLC separation and 
quadrupole time-of-flight (QTOF) accurate mass detection to investigate the whole 
metabolome in the urine of rats. After silver administration, uric acid and allantoin were 
found to be increased in female rat urine. One possible explanation for this increased purine 
metabolism could be the induction of oxidative stress and cytotoxicity with simultaneously 
DNA degradation. This was supported by in vitro studies, where ROS were found increased 
(68). 
In another study, Li’s team have found that Daphnia magna exhibited significant changes 
in their metabolic profile following the two size Ag NP and Ag+ exposure. Most of the 
metabolic biomarkers for Ag NP exposure were identical to those of the Ag+-exposed 
groups, suggesting that the dominant effects of both Ag NPs were due to release of Ag+. The 
observed metabolic response to the Ag+ released from both the Ag NPs is an indicative of 
disturbances of energy metabolism and oxidative stress in D. magna. Moreover, the levels 
of lactate were elevated in all Ag NP-treated groups but not in the Ag+-treated groups. This 
suggests a mechanism of enhancement of anaerobic metabolism being induced by Ag NPs 
(69). 
1.3.5.4. Titanium dioxide (TiO2) nanoparticles 
Due to their high stability, anticorrosion and photocatalytic properties, TiO2NPs are 
abundantly produced and capable of a great variety of applications in life science and 
industry, such as paints, coatings, plastics, skin care products, foods and some 
pharmaceuticals. However, some studies reported that TiO2NPs can cause pulmonary 
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inflammation, fibrosis and DNA damage, while chronic exposure can be carcinogenic. 
(70,71). Still, the biological effects of TiO2NPs exposure and the mechanism underlying the 
body response are still not well established. In order to elucidate the pathological, metabolic 
and toxicological response, metabolomic techniques were employed (70–73). 
In one of those studies, metabolomic response to TiO2NPs treatment supported in vitro 
findings that reported cellular toxicity and induction of oxidative stress upon treatment of 
HaCaT cells with TiO2NPs. Samples were analysed by either gas chromatography/mass 
spectrometry (GC/MS) or liquid chromatography/mass spectrometry (LC/MS) where 
several metabolites were found significantly altered, such as coenzyme A, carnitine and acyl-
carnitines. Also, a lower level of nucleosides and nucleotides was observed. These changes 
indicated that TiO2NPs have significant effects on anabolic pathways and energy metabolism 
(71). In another study, numerous changes in endogenous metabolites were observed in the 
1H NMR spectra of female Wistar rats’ urine and serum samples following TiO2NPs 
administration. TiO2NPs were suggested to cause disturbances in energy metabolism, amino 
acid metabolism and gut microflora, which may be attributable to their toxic effects on the 
liver and heart (70). Earthworms have also been exposed to TiO2NPs and the metabolomic 
response revealed increased levels of alanine and other amino acids and decreased maltose, 
reflecting significant alterations in the underlying network of earthworm metabolic pathways 
(72). 
With Garcia-Contreras’ team research, it was found that TiO2 NPs significantly reduced 
most of amino acids, while, ophthalmate, a-aminoadipate, kynurenine and β-alanine 
increased. Notably, many metabolites in urea cycle, including asparagine, arginine, 
argininosuccinate, citrulline, ornithine and the metabolites in its downstream polyamine 
pathways, such as putrescine and spermidine also decreased, indicating that the activation of 
urea cycle and polyamine pathway was stronger than those of the other pathways. TCA cycle 
metabolites also showed different patterns. First, citrate, cis-aconitate and isocitrate showed 
a gradual decrease, possibly using the acetyl-CoA produced by oxidative decarboxylation of 
pyruvate. Second, a-ketoglutarate, succinate, fumarate and malate remained almost constant. 
Metabolic changes were also seen in the levels of GSH and GSSG, where the concentration 
of GSH was nearly one order higher than that of GSSG, which favoured the cells toward 
oxidative state (73). 
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1.3.5.5. Micellar nanocarriers and liposomes 
Micellar nanocarriers are self-assembling nano-sized colloidal particles with a 
hydrophobic core and hydrophilic shell. Nowadays they are successfully used as 
pharmaceutical carriers for low water solubility drugs and have demonstrated a series of 
attractive properties as drug carriers since they can overcome some toxicities caused by the 
toxic organic excipients of the drugs (74,75). Katragadda’s team has performed 1H NMR of 
mice tumour extracts in different treatment groups noticing significantly altered metabolic 
activities. The results suggested that paclitaxel/17-AAG loaded micelles normalized glucose 
consumption in the tumour by reducing glucose uptake and blocking aerobic glycolysis. This 
led to significantly decreased levels of glucose in the tumour, as well as lactate and alanine, 
which are end products of glycolysis (75). 
Liposomes are small vesicles composed of one or more lipid membranes surrounding 
discrete aqueous compartments. These vesicles can encapsulate water-soluble drugs in their 
aqueous spaces and lipid-soluble drugs within the membrane itself. A liposomal drug 
delivery system can alter the in vivo behaviour, attenuate adverse side effects and improve 
the therapeutic index of the encapsulated drug. Cong’s team performed a urine metabolic 
study based on UPLC/TOF-MS for the assessment of cumulative cardiotoxicity in rats. Their 
study showed that the drug pirarubicin (THP) causes systemic or cardiac toxicity via a 
significant decrease in the intermediary metabolic pathways associated with the key energy 
production. Thus, a diminution of metabolites associated with the TCA cycle, glycolysis, 
pentose phosphate and amino acid synthesis pathways was observed. These considerations 
are important for the safety assessment of liposomal drug delivery system (76). 
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Table II – Overview of metabolomic studies of nanomaterials with biomedical applications. 
Nanomaterial Cell model Animal model Analytical technique Sample type 
Year of publication 
(Ref.) 
SiO2 NP 
HeLa - 1H NMR (HRMAS) Cell extracts 2013 (60) 
MRC-5  - GC/MS or LC/MS Cell extracts 2012 (59) 
- Sprague Dawley rats 1H NMR Liver tissue 2013 (58) 
USPIO 
RAW264.7 - 1H NMR (HRMAS) Cell extracts 2011 (63) 
- Sprague Dawley rats 1H NMR (HRMAS) Tissue 2011 (64) 
- Sprague Dawley rats 1H NMR Urine and plasma 2010 (65) 
Au NP A549; 16-HBE - 1H NMR Cell extracts 2013 (67) 
Ag NP 
- Wistar Hannover Galas rats HPLC-QTOF-MS Urine 2012 (68) 
- Daphnia magna 1H NMR Metabolite extracts 2015 (69) 
TiO2 NP 
HaCat - GC/MS or LC/MS Cell extracts 2013 (71) 
- Eisenia fetida earthworms 1H NMR E. fetida tissue 2011 (72) 
- Wistar rats 1H NMR Urine and serum 2010 (70) 
HGF - CE-TOF-MS Cell extracts 2015 (73) 
Micellar 
nanocarriers  
- 
Human ovarian cancer SKOV-
3 cells xenograft in mice 
1H NMR Tumour tissue 2013 (75) 
Liposomes  Sprague Dawley rats UPLC/TOF–MS Urine 2012 (76) 
Cu NP - Wistar rats 1H NMR Urine and serum 2008 (77) 
ZnO2 NP - Rats 1H NMR 
Urine and kidney 
aqueous extracts 
2012 (78) 
Note  1 –  Abbreviations: Silver (Ag); Gold (Au); Copper (Cu); Silica dioxide (SiO2); Titanium dioxide (TiO2); Ultrasmall Superparamagnetic Iron Oxide (USPIO); 
Zinc dioxide (ZnO2); Henrietta Lacks' cells (HeLa); Human Fetal Lung Fibroblast Cells (MRC-5); Mouse leukemic monocyte macrophage cell line), (RAW264.7); 
Adenocarcinomic human alveolar basal epithelial cells (A549); Human bronchial epithelial cells (16-HBE); spontaneously immortalized, Human keratinocyte line 
(HaCat); Human gingival fibroblast cells (HGF); High-performance liquid chromatography (HPLC); Quadrupole-time-of-flight (QTOF); Mass spectrometry (MS); 
Nuclear Magnetic Resonance (NMR) Spectroscopy; Ultra Performance Liquid Chromatography (UPLC); Gas Chromatography (GC); Liquid Chromatography (LC); 
High Resolution Magic Angle Spinning (HRMAS).
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1.4. Scope and aims of this thesis  
The main goals of this work were: 
i) To characterize the metabolic profile of the macrophage cell line RAW 264.7. 
Macrophages are specialized host defence cells found in the reticuloendothelial 
system, responsible for maintain cellular and organism homeostasis (12,79,80). 
Through an endocytic process, macrophages play an important role in the uptake of 
NPs from the circulation, their metabolism and degradation, thus being considered a 
relevant model for nanotoxicological studies. Thus, they were selected for this study 
and it is expected that their metabolic content may be reflective of their biochemical 
status. 
ii) To assess the impact of silk nanoparticles (SNPs) on macrophage metabolism, by 
identifying the most affected metabolites and pathways. 
Both aqueous and lipid cell extracts were considered for this purpose in order to 
obtain a more comprehensive view of the metabolome. 
iii) To examine the dependence of metabolic effects on exposure concentration and 
duration. 
Three time points and two SNPs concentrations, selected, respectively, based on 
the cells growth curve and viability assays, were tested. 
iv) To evaluate the sensitivity of NMR metabolomics to provide mechanistic insight 
into cell-NPs interactions. 
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2.1. Materials and methods 
This work has been carried out in the framework of a collaboration with the Strathclyde 
Institute of Pharmacy and Biomedical Sciences of the University of Strathclyde, Glasgow 
(UK), where cell culture studies and samples for the metabolomics studies were prepared 
and collected by Dr P. Seib. The NMR acquisition, processing and analysis were then 
performed at the University of Aveiro, within the framework of this thesis.  
 
2.1.1. Silk nanoparticles (SNPs) 
Uncoated, spherical silk nanoparticles (ca. 100 nm in diameter) were generated at 
Strathclyde from B. mori silk, according to the procedure described in (19). For all cell 
exposure experiments, a 10 mg/ml stock in ddH2O was generated and gamma sterilised. 
 
2.1.2. Cell culture studies 
Murine RAW 264.7 macrophages were seeded at a density of 1.5 × 104 cells/cm2, the 
required cell density to provide a sufficiently strong signal for NMR analysis. For 
proliferation and cytotoxicity studies, cells were seeded in 100 μL of complete medium into 
96 well plates. For metabolomics studies, 60 mm diameter Petri dishes were used and scaled 
accordingly. For all studies, cells were plated and then allowed to recover over night before 
commencing measurements.  
In order to establish the cells growth curve, cell proliferation was monitored using MTT 
(5mg/mL in PBS). Briefly, cells were incubated with 20 μL of MTT for 5 h. Next, the 
medium was aspirated and replaced with 110 μL of DMSO and incubated for 10 minutes to 
dissolve formazan crystals. Finally, 100 μL of the product was transferred to a reading plate 
and absorbance was measured at 570 nm. Data were expressed as a percentage of the 
maximum absorbance determined in this study. 
 
2.1.3. Cytotoxicity assessment of SNPs 
The cytotoxicity of SNPs was assessed using the colorimetric MTT assay, which 
measures the formation of purple formazan. Cell viability was calculated as a percentage by 
using untreated cells as a benchmark for 100% viability, since the tetrazolium salt MTT can 
only be metabolized by living cells. Therefore, the dye intensity is proportional to the 
number of viable cells (81). Briefly, cells were incubated with a 2.5 to 1000 μg/mL SNPs; 
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5h before the end of a 24h, 48h and 72h exposure time 20 μL of MTT was added to cells and 
incubated. Next, the medium was aspirated and replaced with 100 μL of DMSO and 
absorbance was measured at 570 nm.  
 
2.1.4. Samples for metabolomics studies 
For metabolomics, macrophages were exposed to two concentrations of SNPs (low, 10 
μg/mL and high, 500 μg/mL) and three sample types collected from each dish: culture 
medium, cell aqueous extract and cell lipid extract. Samples from control dishes (no SNPs 
added) were also collected. Four independent assays were performed (with duplicates for 
controls), so that for each concentration of SNPs, there were four dishes, whereas eight 
dishes were available for controls.  
After collecting and centrifuging a medium aliquot, the remaining medium was aspirated 
and each dish was washed twice with PBS. Then, intracellular aqueous metabolites and lipids 
were extracted using a dual phase extraction procedure adapted from Teng et al. (82). 
Briefly, 650 μL of cold methanol 80% was added, to stop metabolic activity, and the cells 
were scraped off the dish and vortexed for 1 min in microcentrifuge tubes containing 0.5 
mm glass beads, to aid cell breakage. Chloroform (260 μL + 260 μL) and water (220 μL) 
were then added to each sample, each addition being followed by 1 min vortexing, and the 
samples were left to rest on ice for 10 min. After centrifuging at 2000g for 15 min, the upper 
aqueous phase and the lower organic phase were then carefully transferred into new vials, 
dried under vacuum and stored at -80ºC. The dried samples were sent by express mail and 
stored at -80ºC until NMR analysis. 
 
2.2. NMR Spectroscopy 
2.2.1. Sample preparation for NMR 
Dried aqueous samples were reconstituted in 600 μL of deuterated phosphate buffer (PBS, 
100mM, pH 7.4) containing 0.1 mM TSP, while organic phase extracts were reconstituted 
in deuterated chloroform containing 0.03% TMS. For NMR analysis, 550 μL of each sample 
were transferred into 5 mm NMR tubes. The medium samples remain stored for later analysis 
and will not be considered within this thesis. 
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2.2.2. Acquisition and processing of 1H NMR spectra 
All experiments were acquired on a Bruker Avance DRX spectrometer operating at 
500.13 MHz for 1H, using a 5 mm TXI probe, at 298 K. Standard 1D spectra (pulse programs 
‘noesypr1d’ and ‘zg’ in Bruker library, for aqueous and lipid extracts respectively) were 
acquired with a 6510 Hz spectral width, 32 K data points, a 2 s relaxation delay (d1), and 
256 scans. Data processing was performed using TopSpin 3.2 (Bruker Biospin, Rheinstetten, 
Germany). The free induction decay (FID) signals were processed by exponential 
multiplication (using a line broadening window function LB 0.3 Hz) and zero filling to 64 
K data points prior to Fourier transformation. All 1D spectra were manually phased and 
baseline corrected. The chemical shifts were referenced internally to the TSP/TMS signal at 
δ 0.00 ppm (aqueous/lipid extracts). 2D 1H-1H total correlation (TOCSY) spectra, 1H-13C 
heteronuclear single quantum correlation (HSQC) spectra and J-resolved spectra were also 
registered for selected samples to assist spectral assignment. The main acquisition and 
processing parameters for these experiments are provided in the following tables: 
 
Table III – Main parameters used for the acquisition and processing of 1D 1H NMR (500 MHz) 
spectra of aqueous and lipidic extracts. 
1D 1H NMR (500 MHz) 
Acquisition parameters 
Experiment  standard 1D 
Pulse programme ª (aqueous/lipid extracts) noesypr1d/zg 
Number of scans, NS  256/256 
FID data points, TD  32768/32768 
Spectral width (ppm)  14.00/14.00 
Acquisition time, ACQ (s)  2.34/2.34 
Relaxation delay, RD (s)  2/2 
Mixing time, tm (ms) (aqueous extracts) 100 
Processing parameters 
Window function  exponential 
Spectrum data points, SI  65536 
Line broadening, LB (Hz)  0.3 
ª Bruker library 
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Table IV - Main parameters used for the acquisition and processing of 2D NMR (500 MHz) 
spectra of aqueous and lipid extracts. 
2D NMR (500 MHz) 
 Acquisition parameters 
Experiment  1H-1H TOCSY 1H-13C HSQC J – Resolved 
Pulse programme ª dipsi2phpr hsqcetgp jresgpprqf 
FID data points 1st dimension [F1]  4096 4096 8192 
FID data points 2nd dimension [F2]  156 200 40 
Number of scans  96 128 80 
Spectral width [F1] (ppm)  16.02 16.02 16.02 
Spectral width [F2] (ppm)  16.02 165.6 0.09 
Relaxation delay, RD (s)  2 4 2 
Mixing time, tm (ms)   30  
 Processing parameters 
Spectrum data points [F1], SI  4096 4096 16384 
Spectrum data points [F2], SI  2048 2048 1024 
Line broadening [F1], LB (Hz) 0.3/0.3 0.3 0.3 
Line broadening [F2], LB (Hz)  1.0 0.3 
ª Bruker library; 
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2.3. Multivariate analysis 
2.3.1. Pre-treatment and multivariate analysis of NMR spectra 
The preparation of NMR data for multivariate analysis (MVA) requires the construction 
of data matrices (𝑛 × 𝑚 (rows × columns) of n observations (samples) and m variables (peak 
intensities)), either using the full spectra or spectral regions (buckets). In this work, 0.01 
ppm buckets were considered, after excluding selected regions for building the data matrix, 
namely the suppressed water signal (in aqueous extracts only) and additional signals found 
to result from contamination, either from the medium not completely washed off the dishes 
or from solvents present in the evaporation system (see table V). Each spectrum was exported 
from Amix-Viewer (version 3.9.14, BrukerBiospin, Rheinstetten) and normalized by total 
spectral area, in order to make the data from all samples comparable with each other.   
Using SIMCA – P 11.5 software (Umetrics, Umeå, Sweden), the resulting data were scaled 
to Unit Variance (UV), giving equal variance to all variables, and PCA and PLS-DA were 
applied. The results were obtained in the form of scores scatter plots, representing the 
distribution of samples in the model, and corresponding loading plots, to provide information 
on which metabolites were responsible for the pattern observed in the scores plot. The 
loading profiles were obtained by multiplying the loading weights w (representative of the 
correlation of the x variable of the NMR spectra with y class), by the standard deviation. 
Next, the loadings were coloured by the variable importance in the projection (VIP), for the 
discrimination between the classes, using the R software version 2.15.0 (R Development 
Core Team, Vienna, Austria, 2012). To evaluate the quality of the models, a default seven-
fold internal cross validation was used, from which R2 and Q2 values, respectively reflecting 
explained variance and predictive capability, were extracted. Generally, the values of Q2 
between 0 and 1 suggest some predictive character but the reliability increases as Q2 
approaches 1. However, higher R2 and Q2 values are desirable (83). 
Hierarchical cluster analysis (HCA) was also performed, based on the Pearson correlation 
coefficient with single linkage, using the GENE-E software 
(http://www.broadinstitute.org/cancer/software/GENE-E/index.html) applied to same the 
data matrix.  
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Table V – Information about the 1H NMR matrices used for MVA. 
Sample type  Aqueous extracts Lipid extracts 
Rows, n samples  95 47 
Columns, m variables (intensities)  39391 20973 
Spectral interval (ppm)  0.5 – 10 0.5 – 6 
Exclusion areas (ppm)   (1.533 – 1.562) 
(1.915 – 1.925) 
(2.232 – 2.245) 
(2.362 – 2.372) 
(2.729 – 2.737) 
(3.244 – 3.258) 
(3.348 – 3.366) 
(4.634 – 5.00) 
(7.28 – 7.72) 
(1.453, 1.75) 
(2.15, 2.74) 
(3.45, 3.51) 
(5.57, 5.6) 
Integration mode  Sum of absolute intensities 
 
 
2.3.2. Spectral integration and univariate statistics 
To evaluate metabolite quantitative variations, selected signals in the 1D spectrum were 
integrated using Amix-Viewer (version 3.9.14, BrukerBiospin, Rheinstetten) and 
normalized by the total spectral area. Spectral integration was performed by calculating the 
area under a certain signal for which integration limits were manually defined. 
Data normality was assessed through the Shapiro test. For normal distributed data, the t-
test was then applied, and for not normally distributed data, the Wilcoxon test was used. The 
p-value for each metabolite was considered significant when it was lower than 0.05 
(confidence level 95 %). Also, for each metabolite, the percentage of variation and respective 
error were calculated, along with the effect-size (d) and respective 95 % confidence interval. 
The p-value and effect-size obtained by the statistical tests allowed the significance and 
magnitude of the differences between the means of the two classes to be assessed. The 
resulting data was plotted into a heat map using Matlab 7.14.0.739 (The MathWorks Inc., 
Massachusetts, USA) to help visualizing the most significant variations. 
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3.1. Metabolic profile of murine macrophages assessed by 1H NMR 
spectroscopy 
3.1.1. Metabolic composition of murine macrophages (RAW 264.7 cell line): 
spectral assignment based on 1D and 2D NMR experiments 
By reflecting substrate utilization and production within intermediary metabolism, the 
metabolic composition of cells under different conditions may help assessing the cells’ 
physiopathological status and their response to different stimuli. Here, the basal metabolic 
composition of murine macrophages (RAW 264.7 cell line) was investigated through the 
analysis of 1D and 2D 1H NMR spectra of aqueous and lipid cell extracts. Figure 8 shows 
the standard 1H NMR spectrum of an aqueous extract from RAW 264.7 cells, where a 
multitude of signals was detected, reflecting the complex sample composition. 
 
Figure 8 – Representative 500 MHz 1H NMR spectrum of an aqueous extract from RAW 264.7 cells. Some 
assignments are indicated: three-letter code used for amino acids, ADP adenosine diphosphate, ATP adenosine 
triphosphate, AXP (ADP/ATP), BCAA branched chain amino acids, Cr creatine, NAD Nicotinamide adenine 
dinucleotide, PCr phosphocreatine, PCho phosphocholine, Un unassigned, UXP uridine diphosphate/uridine 
triphosphate (UDP/UTP). 
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The corresponding 2D spectra are shown in Figure 9. The 1H-1H TOCSY spectrum 
(Figure 9A) reveals intramolecular spin-spin connectivities, helping to unambiguously 
identify several compounds with signals overlapped in the 1D spectrum. The 1H-13C HSQC 
spectrum (Figure 9B) was particularly helpful to identify singlets (without TOCSY cross 
peaks) or to aid the assignment of cross peaks still overlapped in TOCSY (taking advantage 
of the larger chemical shift dispersion of 13C resonances). Finally, the J– resolved spectrum 
(Figure 9C) was also useful to distinguish highly overlapped signals and provided 
information on signal multiplicity. Table VI shows the complete list of compounds 
identified, along with their 1H and 13C chemical shifts, measured in 1D and 2D NMR spectra. 
The low-frequency region (δ 0-3) shows resonances from several amino acids, like 
branched chain amino acids, alanine and aspartate, but also organic acids like lactate, acetate 
and pyruvate. In the mid-frequency region (δ 3-5.5), additional intracellular metabolites were 
detected, including creatine, phosphocreatine, glycine, choline-containing compounds, 
taurine, myo-inositol and threonine. Glucose was also present in the spectrum, however it 
was found to arise from residual medium not completely washed off the dishes before 
metabolite extraction. Hence, glucose variations were disregarded since they were not 
induced by macrophages metabolism. The high-frequency region (δ 5.5-10) is characterized 
by signals arising from aromatic amino acids (tyrosine and phenylalanine), organic acids 
(fumarate and formate) but also nucleotides (ADP, ATP, UDP, UTP and NAD+). 
In total, over thirty compounds were identified in the cells aqueous extracts, providing 
significant information on the metabolic composition of RAW 264.7 cells and setting the 
basis for interpreting the silk nanoparticles’ exposure variation discussed ahead. 
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Figure 9 – Expansions of the (A) 1H-1H TOCSY, (B) 1H-13C HSQC and (C) J-resolved spectra of aqueous 
supernatants prepared from murine macrophages (RAW 264.7 cell line). Signals are numbered in 
accordance with Table VI. 
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Table VI – Assignment of resonances in the NMR profile of RAW 264.7 aqueous extract 
of cells (s, singlet; d, doublet; t, triplet; m, multiplet; dd, doublet of doublets). 
No. Compound δ 1H in ppm (multiplicity, assignment) / δ 13C in ppm 
1 Acetate 1.92 (s, β-CH3)/26.3 
2 ADP 4.25 (m, C5’H, ribose); 4.62 (m, C2’H, ribose); 6.16 (d, 
C1’H, ribose) /89.4; 8.28 (s, C8, ring); 8.54 (s, C2, ring) 
3 Alanine 1.49 (d, β-CH3)/18.9; 3.78 (m, α-CH)/57.2 
4 β -Alanine 2.56 (t, β-CH2); 3.18 (t, α-CH2) 
5 Aspartate 2.69 (dd, β-CH); 2.82 (dd, β’-CH); 3.90 (dd, α-CH)/63.7 
6 ATP 4.24 (m, C5’H, ribose); 4.29 (m, C5’’H, ribose); 4.41 (m, 
C4’H, ribose); 4.62 (m, C2’H, ribose); 6.15 (d, C1’H, 
ribose)/89.4; 8.27 (s, C2, ring); 8.55 (s, NH, ring) 
7 Choline 3.22 (s, N(CH3)3); 3.54 (CH2)NH)); 4.07 (m, CH2(OH)) 
8 Creatine 3.04 (s, CH3); 3.93 (s, CH2) 
9 Formate 8.46 (s, CH) 
10 Fumarate 6.52 (s, CH) 
11 α-Glucose 3.41 (m, C4H)/72.5; 3.55 (dd, C2H)/74.1; 3.73 (m, 
C3H)/76.2; 3.83 (m, C6H); 3.85 (m, C5H); 5.24 (d, C1H) 
12 β-Glucose 3.26 (dd, C2H); 3.42 (m, C4H)/72.3; 3.47 (m, C5H); 3.49 
(t, C3H)/79.0; 3.78 (m, C6H)/63.8; 3.90 (dd C6’H)/63.7; 
4.66 (d, C1H) 
13 Glutamate 2.06 (m, β-CH)/29.9; 2.13 (m, β’-CH); 2.35 (m, γ-
CH2)/36.4 
14 Glutamine 2.14 (m, β-CH2)/29.6; 2.45 (m, γ-CH2)/33.8 
15 Glutathione, reduced 
(GSH) 
2.17 (m, β-CH2, Glu); 2.56 (m, γ-CH2, Glu); 2.98 (m, β-
CH2, Cys); ); 3.78 (α-CH)/46.1; 4.57 (m, α-CH2, Cys); 
8.37 (NH, Gly); 8.56 (NH, Cys) 
16 Glutathione, 
oxidized (GSSG) 
2.17 (m, β-CH2, Glu); 2.56 (m, γ-CH2, Glu); 2.98 (m, β-
CH2, Cys)/41.8; 3.31 (m, β-CH2, Cys); 3.78 (α-
CH)/53.8; 4.77 (α-CH2, Cys) 
17 Glycine 3.56 (s, α-CH2)/44.5 
18 Histidine 3.23 (m, β-CH2); 7.08 (s, C4H, ring); 7.87 (s, C2H, ring) 
19 Isoleucine 0.94 (t, δ-CH3); 1.01 (d, β'-CH3); 1.26 (m, γ-CH2); 1.48 
(m, γ’-CH2); 1.98 (m, β-CH); 3.69 (d, α-CH) 
20 Lactate 1.33 (d, β-CH3)/22.9; 4.12 (m, α-CH)/71.6 
21 Leucine 0.96 (d, δ-CH3); 0.97 (d, δ'-CH3); 1.70 (m, γ-CH);1.72 (m, 
β-CH2); 3.74 (t, α-CH) 
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No. Compound δ 1H in ppm (multiplicity, assignment) / δ 13C in ppm 
22 Lysine 1.48 (m, γ-CH2); 1.73 (m, δ-CH2); 1.92 (m, β-CH2); 3.02 
(t, ε-CH2); 3.76 (t, α-CH) 
23 Myo-inositol 3.28 (t, C5H)/77.4; 3.54 (C1H, C3H); 3.63 (dd, C4H, 
C6H)/75.5; 4.07 (t, C2H)/75.2 
24 NAD+ 4.23 (m, A5’); 4.36 (m, A4’); 4.39 (m, A4’/N5’); 4.44 
(dd, N3’); 4.50 (m, A3’); 4.54 (m, N2’); 6.00 (d, N1’); 
6.10 (d, A1’); 8.20 (s, A2); 8.19 (N5); 8.43 (s, A8); 8.83 
(d, N4); 9.14 (d, N6); 9.34 (s, N2) 
25 Phenylalanine 3.14 (m, β-CH); 3.27 (dd, β'-CH)/56.4; 3.98 (m, α-CH); 
7.33 (d, C2H, C6H, ring)/131.9; 7.39 (d, C4H, ring); 7.43 
(t, C3H, C5H, ring) 
26 Phosphocholine 3.23 (s, N(CH3)3)/57.0; 3.62 (m, N-CH2); 4.17 (m, PO3-
CH2) 
27 Phosphocreatine 3.05 (s, CH3); 3.95 (s, CH2) 
28 Proline 2.00 (m, γ-CH2); 2.06 (m, β-CH); 2.34 (m, β'-CH); 3.34 
(dt, δ-CH); 3.40 (dt, δ'-CH); 4.13 (dd, α-CH) 
29 Pyruvate 2.36 (s, β-CH3)/23.2 
30 Succinate 2.40 (s, CH2) 
31 Taurine 3.27 (t, S-CH2)/50.7; 3.43 (t, N-CH2)/38.3 
32 Threonine 1.34 (d, γ-CH3); 3.59 (d, α-CH)/63.5; 4.26 (m, β-CH) 
33 Tyrosine 3.08 (m, β'-CH); 3.21 (m, β-CH); 3.95 (m, α-CH); 6.91 
(d, C3H, C5H, ring); 7.20 (d, C2H, C6H, ring) 
34 UDP 4.23 (m, C5’H, ribose); 4.27 (m, C4’H, ribose); 4.40 (t, 
C2’H, ribose); 4.44 (t, C3’H, ribose); 5.97 (s, C1’H, 
ribose); 5.98 (d, C6, ring); 7.99 (d, C5, ring) 
35 Unassigned (Un.) 1 1.64 (s) 
36 Un. 2 3.16 (m) 
37 Un. 3 5.38 (m) 
38 Un. 4 5.86 (m) 
39 UTP 4.27 (m, C5’H, ribose); 4.30 (m, C4’H, ribose); 4.42 (t, 
C2’H, ribose); 4.45 (t, C3’H, ribose); 5.97 (s, C1’H, 
ribose); 5.99 (d, C6, ring); 7.99 (d, C5, ring) 
40 Valine 0.99 (d, γ-CH3); 1.05 (d, γ'-CH3); 2.28 (m, β-CH); 3.62 
(d, α-CH) 
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In regard to lipid extracts, a typical 1H spectrum is shown in Figure 10. This spectrum 
shows broader signals, compared to that of aqueous extracts, as the larger lipid molecules 
show faster transverse relaxation (shorter T2 relaxation time constants, hence larger signal 
width). Also, there is significant overlap between signals of different lipid species, for 
instance, it is difficult to distinguish the different fatty acids composing triglycerides or 
glycerophospholipids. Still, a number of lipid compounds could be distinguished based on 
specific resonances. Cholesterol and phosphatidylcholine (PTC), two major components of 
cell membranes, were found to be main contributors to the lipid extract spectrum. 
Phosphatidylethanolamine (PTE), sphingomyelin (SM) and smaller amounts of neutral 
lipids (triglycerides and cholesterol esters were also detected). Table VII shows the complete 
list of lipid compounds identified, along with their 1H and 13C chemical shifts, measured in 
1D and 2D NMR spectra (Fig. 11). This assignment is in agreement with the lipid 
composition previously described for RAW 264.7 cells (84,85). 
 
 
Figure 10 – Representative 500 MHz 1H NMR spectrum of a lipid extract from RAW 264.7 cells. Some 
assignments are indicated: FA Fatty Acids/Fatty acyl chains, PTC phosphatidylcholine, PTE 
phosphatidylethanolamine, SM sphingomyelin, TG triglyceride. 
                                                                  Chapter 3 – Results and Discussion 
   45 
 
 
 
 
 
Table VII – Assignment of resonances in the NMR profile of RAW 264.7 lipid extract of 
cells (s, singlet; d, doublet; t, triplet; m, multiplet; dd, doublet of doublets). 
No. Compound δ 1H in ppm (multiplicity, assignment) / δ 13C in ppm 
1 Cholesterol 
0.68 (s, CH3-18)/11.9; 0.86 (d, CH3-26); 0.87 (d,CH3-
27)/22.4; 0.91 (d, CH3-21)/18.6; 1.01 (s, CH3-19)/19.3; 
1.05-1.19 (m, multiple protons); 1.26 (d) 1.42-1.55 (m, 
multiple protons); 1.78-1.87 (m, multiple protons); 
1.95-2.02 (m, multiple protons); 2.23/35.9; 2.26 (m, 
CH2-4); 3.48-3.55 (m, CH-3); 5.34 (m, CH-6)/122.02 
2 Cholesterol ester 1.02 (s, CH3-19); 1.57 (m, multiple protons); 1.84 
(m,CH2-2); 2.31 (m, CH2-4); 4.62 (m, CH-3)/48.7 
3 Fatty acyl chains (mainly 
in phospholipids) (FA) 
0.88 (t, CH3(CH2)n); 1.25 (m, (CH2)n)/29.6; 1.25 (m, 
(CH2)n)/31.8; 1.55-1.65 (m, -CH2-CH2CO)/27.0; 1.98-
2.09 (m, -CH2CH=)/27.0; 2.25-2.35 (m,-
CH2COOR)/21.1; 2.77-2.87 (m, =CHCH2CH=)/25.6; 
5.35 (m, -HC=CH-)/130.0 
Figure 11 – Expansion of the 1H-1H TOCSY spectrum of a lipid extract prepared from murine macrophages 
(RAW 264.7 cell line). Signals are numbered in accordance with Table VIII. 
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No. Compound δ 1H in ppm (multiplicity, assignment) / δ 13C in ppm 
4 Phosphatidylcholine 
(PTC) 
0.89/14.1; 1.26-1.37 (multiple protons)/29.5;1.30/22.6; 
1.59(s)/24.6; 2.06/27.2; 2.28-2.34 (m)/34.1 ; 2.81 (s); 
3.35/54.8 (s, N(CH3)3; 3.73 (CH2-N)/67.0; 3.95 
(Glyceryl CH2 sn3)/63.6; 4.12, 4.38 (Glyceryl CH2 
sn1); 4.40 (CH2-OP); 5.24 (Glyceryl CH sn2); 
5.35/129.8 
5 Phosphatidylethanolamine 
(PTE) 
3.18 (s, CH2-N); 3.55 (Glyceryl CH2 sn1)/48.8; 3.92 
(Glyceryl CH2 sn3); 4.12 (CH2-OP)/62.7; 5.15 
(Glyceryl CH sn2) 
6 PTE plasmalogen 1.27 ((CH2)n); 1.99 (-CH=CH-CH2); 4.34 (-CH=CH-); 
5.91 (-CH=CH-) 
8 Sphingomyelin (SM) 3.32 (s, N(CH3)3); 4.40 (-CH=CH-)/50.4; 5.70 (-
CH=CH-) 
9 Triglycerides (TG) 0.82 (t, CH3); 4.12, 4.28 (Glyceryl CH2 sn1/sn3); 5.27 
(Glyceryl CH sn2) 
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3.1.2. Time-related changes in control cells 
 As three time points were considered in this study (24, 48 and 72h), the variations in 
control cells over culture time were inspected, in order to assess the possible influence of 
sampling time on the metabolic profile. The visual comparison of average spectra from 
control aqueous extracts suggests that there are some differences along time in some small 
metabolites (Fig. 12). Multivariate analysis further confirms this observation, as samples 
from different time points are reasonably separated in the PCA scores scatter plot along PC1 
(Figure 13). By analysing the corresponding loadings (not shown), it becomes clear that 
while branched chain amino acids, lysine, pyruvate, choline compounds and aromatic amino 
acids decreased along culture time, alanine, glutamate, creatine, phosphocreatine, myo-
inositol, glycine, lactate and nucleotides increased. These variations reflect the cells 
metabolic adaptations during growth and highlight the dynamic nature of the metabolome. 
 
Figure 12 – Average 1H NMR spectra of aqueous extracts of RAW 264.7 cells at 24, 48 and 72 hours. 
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In regard to lipid extracts, the variations in control cells also revealed the influence of 
sampling time on the metabolic profile, as seen through both visual comparison of the 
average spectra (Fig. 14) and multivariate analysis (Fig. 15). By analysing the corresponding 
loadings (not shown), it becomes clear that while triglycerides, fatty acyl chains, mainly in 
phospholipids, and sphingomyelin did not show significant differences along culture time, 
cholesterol, phosphatidylcholine, phosphatidylethanolamine, and plasmalogen increased, 
possibly reflecting changes in membrane composition during cell growth.  
Figure 14 - Average 1H NMR spectra of lipid extracts of RAW 264.7 cells at 24, 48 and 72 hours 
Figure 13 - PC1 vs PC2 scores scatter plot obtained by PCA of 1H NMR spectra from aqueous 
extracts of control cells collected at different time points. 
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Figure 15 - PC1 vs PC2 scores scatter plot obtained by PCA of 1H NMR spectra from lipid extracts of 
control cells collected at different time points. 
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3.2. Impact of silk nanoparticles on macrophage metabolism 
3.2.1. Cytotoxicity results 
 In order to assess the growth characteristics of the RAW cell line and determine the best 
time range for evaluating the effects of silk nanoparticles (SNPs), a growth curve has been 
established (Figure 16). The initial cell density plated on each dish was chosen in order to 
have sufficient cells for metabolomics already at the early time point (24h). The cells were 
found to reach confluence about day 4 and to be in the exponential growth phase (in which 
the cell population doubles at a characteristic rate) from 24 to 72h. Thus, this time range was 
selected for the SNPs exposure studies, as during this phase the cells are more vulnerable to 
external stimuli. Investigating the cellular response in the first 72 hours exposure also allows 
to maximize the difference between control and treatment groups and minimize assay 
artefacts due to confluence.  
 
To investigate the effects of silk nanoparticles on cell viability and determine the IC50 
value (that indicates the concentration needed to inhibit cell viability by half), RAW cells 
were exposed to increasing concentrations of SNPs. After 24, 48 and 72 hours of incubation, 
MTT solution was added to each of the samples and cell viability was assessed, as described 
in the experimental section. 
For 24 and 48h, cell viability did not decrease below 60% across the tested concentration 
range of silk nanoparticles, with IC50’s > 1000 μg/mL at both time points (Figure 17). 
Curiously, the decrease in cell viability upon exposure to 2.5-50 μg/mL SNPs seemed to be 
Figure 16 – Growth curve of RAW 264.7 cells. Cells were plated at a density of 1.5 × 104 cells/cm2 and 
cell growth was monitored daily. (n=3 independent experiments. Error bars represent standard deviation). 
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more abrupt at 24h. At 72h of exposure, cell viability decreased steadily with increasing SNP 
concentration, reaching about 40% of cell viability for the maximum concentration tested 
(1000 μg/mL). However, it is possible that cell overgrowth at 72h may also affect cell 
viability and that the observed decrease does not exclusively arise from SNPs toxicity.  
 
 
  
Figure 17 – Cytotoxicity of silk nanoparticles (SNPs) on RAW264.7 cells. Cells were exposed to 
nanoparticles for 24 h, 48 h or 72 h and cell viability was determined by the MTT assay. (n=4 independent 
experiments, ± standard error of the mean). 
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3.2.2. Effects on the metabolome of macrophages assessed by 1H NMR 
spectroscopy of cellular aqueous extracts 
This section presents the variations in the metabolome of RAW 264.7 cells in response 
to silk nanoparticles (SNPs) when compared to controls and taking into account different 
factors, such as the concentration and duration of exposure.  
Figure 18 shows the average 1H NMR spectra of aqueous extracts from RAW 264.7 cells 
after 48 hours of exposure to SNPs at low (10 µg/mL) and high (500 µg/mL) concentrations, 
and their corresponding controls (non-exposed). The visual comparison of the three spectra 
allowed several differences to be suggested, namely in the levels of branched chain amino 
acids (BCAA), creatine (Cr), phosphocreatine (PCr), glycine, lactate, formate and tyrosine 
(increased in exposed cells) and of alanine, aspartate, threonine, myo-inositol, and 
nucleotides (decreased in exposed cells). Additionally, these spectra clearly demonstrate that 
SNPs caused the metabolome of RAW 264.7 to change in a concentration-dependent 
manner, with the high concentration causing much stronger effects.  
 
Figure 18 – Average 1H NMR spectra of aqueous extracts of RAW 264.7 cells after 48h exposure to SNPs, 
with low and high concentration of SNPs. 
(a) 
(a) 
(b) 
(b) 
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To evaluate the influence of both SNP concentration and exposure time on the metabolic 
responses to silk nanoparticles, multivariate analysis was performed. As a first approach to 
unveil trends and clusters within the samples, unsupervised methods, namely Principal 
Component Analysis (PCA) and Hierarchical Cluster Analysis (HCA) were applied.  
The scores scatter plot resulting from applying PCA to the spectral profiles (Figure 19A) 
showed a trend for a time- and concentration-dependent response to SNPs. A metabolic 
similarity between low-concentration groups and controls is displayed at all time-points, 
while, within each time point, the high-concentration samples tend to be further away. 
Moreover, there is a trend for separation as a function of time, especially between the 24h 
and the remaining samples. The dendrogram obtained by HCA (Figure 19B) confirms these 
trends: a first node separates the samples exposed to high concentration SNPs for 48 and 72h 
from the remaining samples, whereas further clustering is primarily a function of time.  
Therefore, multivariate analysis was performed considering a sub-set of spectra for each 
exposure period. The respective PCA and PLS-DA quality parameters (R2X and R2Y: 
explained variance of the X and Y matrices; Q2: predictive power) are presented in table 
VIII. 
 
Figure 19 – A) PC1 vs PC2 scores scatter plot obtained by PCA of 1H NMR spectra of cellular aqueous 
extracts corresponding to control conditions and exposure to SNPs at low (10 µg/mL) and high (500 µg/mL) 
concentrations, for different time periods (24, 48, 72h) B) Dendrogram obtained by HCA of the same 
spectral matrix. 
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Table VIII – Statistical parameters obtained by PCA and PLS-DA of controls vs SNPs-
exposed samples, considering different classes (concentrations and time points). 
 PCA PLS-DA 
MODEL R2X R2X R2Y Q2 
24h: CT vs. SNPs L+H 0.286 0.244 0.987 0.510 
48h: CT vs. SNPs L+H 0.333 0.265 0.931 0.198 
72h: CT vs. SNPs L+H 0.370 0.300 0.856 0.156 
24h: CT vs. SNPs L 0.350 0.284 0.993 0.359 
24h: CT vs. SNPs H 0.369 0.329 0.994 0.689 
48h: CT vs. SNPs L 0.367 0.311 0.985 0.563 
48h: CT vs. SNPs H 0.354 0.343 0.998 0.852 
72h: CT vs. SNPs L 0.390 0.267 0.906 -0.025 
72h: CT vs. SNPs H 0.437 0.417 0.990 0.907 
CT – Control; L – Low concentration (10 µg/mL); H – High concentration (500 µg/mL). 
As we can see from this table, the models that best describe the separation between control 
and NP-exposed samples, i.e. which present higher explained variance and a Q2 value closer 
to 1, are the models comparing controls with samples exposed to high concentration SNPs, 
whereas the models with low concentration SNPs show much lower or even negative Q2 
values. Indeed, the overlap between low concentration SNPs and control samples is visible 
in the PCA scores plots obtained for each time point (Figure 20, left), while the high-
concentration samples were separated. Therefore, only the PLS-DA models built for controls 
versus high concentration SNPs were considered in further analysis. The corresponding 
scores show a clear separation between the two classes along LV1 (Figure 20, right), with 
Q2 ≥ 0.7. The respective LV1 loadings (Figure 21), coloured according to variable 
importance in the projection (VIP), allowed the main compounds responsible for this 
discrimination to be identified. These plots suggest that some variations are common to all 
exposure periods, such as the increase in branched chain amino acids, lactate and tyrosine 
(negative loadings) or the decrease in glutamine, taurine, myo-inositol and ATP/ADP 
(positive loadings), whereas other variations seem to be more time-specific.  
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Figure 20 – Scores scatter plots obtained by PCA (left) and PLS-DA (right) of 1H NMR spectra from 
aqueous extracts of control RAW 264.7 cells and cells exposed to SNPs for (A) 24 hours, (B) 48 hours and 
(C) 72 hours. Circles, squares and triangles represent controls, low concentration and high concentration of 
SNPs, respectively. 
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Figure 21 – LV1 loadings w, coloured as a function of variable importance in the projection (VIP), 
corresponding to PLS-DA of 1H NMR spectra from aqueous extracts of control RAW 264.7 cells and cells 
exposed to SNPs for (A) 24 hours, (B) 48 hours and (C) 72 hours. 
A 
B 
C 
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For a more thorough analysis of the magnitude and significance of the variations, 
metabolites with VIP > 1 were integrated in the 1D 1H NMR spectra and the % variation in 
relation to control cells, as well as the effect size (d) and statistical significance, were 
calculated for each metabolite. The results for high concentration of SNPs are summarized 
in Table IX.  
 
Table IX – Metabolite variations in aqueous extracts of RAW 264.7 cells exposed to high 
concentration (500 µg/mL) of SNPs for 24, 48 and 72 hours, compared to control cells. (s, 
singlet; d, doublet; t, triplet; m, multiplet; dd, doublet of doublets). 
 Silk High 24H Silk High 48H Silk High 72H 
Metabolite (δ/ppm a, 
multiplicity) 
% Var. b d c % Var. b d c % Var. b d c 
Alanine (d, 1.49) - - -38.02 ± 4.69 -3.96 ± 1.93 -57.60 ± 5.76 -5.21 ± 2.36 
Aspartate (dd, 2.82) -47.16 ± 5.67 -4.49 ± 2.19 -81.37 ± 7.22 -6.48 ± 2.82 -79.15 ± 28.51 -1.48 ± 1.26 
Creatine (s, 3.04) 377.57 ± 16.66 7.54 ± 3.35 533.77 ± 19.02 8.39 ± 3.53 163.51 ± 21.16 2.58 ± 1.51 
Glutamine (m, 2.35) -13.89 ± 10.44 - -28.08 ± 9.45 -1.83 ± 1.33 46.54 ± 31.37 - 
Glycine (s, 3.56) 21.16 ± 17.27 - 96.37 ± 18.03 3.31 ± 1.73 20.42 ± 10.85 - 
Isoleucine (t, 0.94) 24.12 ± 7.59 1.64 ± 1.32 30.76 ± 6.10 2.64 ± 1.53 78.80 ± 9.20 3.75 ± 1.86 
Leucine (d, 0.96) 17.80 ± 7.16 1.25 ± 1.24 38.61 ± 8.70 2.64 ± 1.53 111.35 ± 9.42 4.21 ± 2.01 
Lysine (t, 3.02) 34.29 ± 8.98 1.64 ± 1.32 55.09 ± 5.80 4.64 ± 2.16 70.59 ± 8.27 4.79 ± 2.21 
Phenylalanine (t, 7.43) 15.21 ± 10.45 - 41.71 ± 8.68 2.59 ± 1.52 57.32 ± 9.65 2.42 ± 1.47 
Phosphocreatine  
(s, 3.05) 
392.82 ± 22.18 5.70 ± 2.63 385.89 ± 21.64 6.28 ± 2.75 - - 
Taurine (t, 3.27) -39.60 ± 6.36 -4.15 ± 2.07 -54.31 ± 5.80 -4.96 ± 2.27 -63.80 ± 11.41 -2.88 ± 1.60 
Threonine (m, 4.26) - - -24.11 ± 4.36 -2.96 ± 1.62 -39.60 ± 5.37 -4.43 ± 2.09 
Tyrosine (d, 6.91) 23.61 ± 8.82 - 52.98 ± 6.41 4.21 ± 2.02 92.37 ± 9.89 4.79 ± 2.21 
Valine (d, 1.05) 26.37 ± 7.30 1.73 ± 1.33 44.91 ± 8.44 3.38 ± 1.75 81.81 ± 10.05 4.32 ± 2.05 
Myo-inositol (t, 4.07) -28.86 ± 12.22 -1.33 ± 1.25 -80.25 ± 9.18 -4.71 ± 2.19 -82.93 ± 16.47 -2.84 ± 1.59 
Choline (s, 3.22) -21.33 ± 13.44 - - - 27.55 ± 22.83 - 
Phosphocholine  
(s, 3.23) 
-41.93 ± 10.99 -2.75 ± 1.61 -69.73 ± 22.89 -1.75 ± 1.31 - - 
Formate (s, 8.46) -29.35 ± 16.51 - 48.07 ± 15.27 1.64 ± 1.29 80.63 ± 13.01 3.14 ± 1.67 
Fumarate (s, 6.52) - - 32.18 ± 21.94 - -65.55 ± 59.86 - 
Lactate (m, 4.12) 84.65 ± 10.22 4.10 ± 2.05 285.09 ± 12.87 9.05 ± 3.79 209.97 ± 19.04 4.79 ± 2.21 
Pyruvate (s, 2.36) -37.42 ± 10.00 -1.88 ± 1.37 -26.38 ± 8.21 -2.03 ± 1.37 - - 
Succinate (s, 2.40) -23.15 ± 9.89 - 27.36 ± 26.11 - 44.92 ± 14.82 1.52 ± 1.26 
ADP (s, 8.54) -23.65 ± 21.51 - -29.16 ± 24.59 - -55.54 ± 13.79 -2.07 ± 1.38 
ATP (s, 8.55) - - -43.27 ± 17.77 -1.94 ± 1.35 -52.09 ± 16.07 -2.18 ± 1.41 
NAD (s, 8.43) 53.59 ± 36.66 - -25.92 ± 12.14 - -50.11 ± 15.35 -1.92 ± 1.35 
UXP (s, 5.97) - - -22.63 ± 15.31 - -30.13 ± 10.44 -1.61 ± 1.28 
Un 1 (s, 1.64) 186.40 ± 9.90 5.61 ± 2.60 120.21 ± 12.67 4.45 ± 2.10 48.03 ± 22.85 1.24 ± 1.21 
Un 2 (m, 3.16) 39.85 ± 11.69 1.76 ± 1.34 114.96 ± 8.82 5.50 ± 2.46 - - 
Un 3 (m, 5.38) 176.04 ± 45.92 - 204.69 ± 23.11 3.79 ± 1.88 - - 
Un 4 (m, 5.86) 115.74 ± 25.96 2.04 ± 1.41 246.41 ± 22.03 4.70 ± 2.18 - - 
a Resonance chosen for signal integration. b % Variation. c d – Effect size in relation to control cells. -, no 
significant variation. 
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Fig. 22 shows the heatmap of effect size values representing the magnitude of variation 
in exposed cells relative to control cells.  
As previously noted, the low concentration SNPs induced few changes in the cells 
metabolome compared to the high concentration SNPs. The time-dependent fluctuations are 
also visible.  
At 24h of exposure, branched chain amino acids, lysine, aromatic amino acids, glycine, 
lactate, creatine, phosphocreatine, NAD+ and unassigned signals were higher than in 
controls, while aspartate, glutamine, cholines, formate, myo-inositol, pyruvate, succinate, 
taurine and ADP were reduced. The profile of the 48h is similar to that of the 24h samples, 
however a stronger metabolic response was visible for almost all metabolites at this time-
point. Also, alanine, threonine, succinate and NAD+ started to show some decrease in 
relation to controls (the last one unlike the first time-point), and formate increased. For the 
72h period, the metabolic response remains similar to the 48h, although glutamine and 
choline were found to increase and fumarate to decrease.  
 
Figure 22 – Heatmap of effect size values of the main aqueous metabolite variations in SNPs-exposed cells 
(low concentration 10 µg/mL; high concentration 500 µg/mL), at different exposure periods (24, 48 and 72 
hours). The colour scale reflects the direction and magnitude of these variations in exposed cells relative to 
control cells (collected for each respective time point). * p < 0.05; ** p < 0.01. 
                                                                  Chapter 3 – Results and Discussion 
   59 
 
3.2.2.1. Proposed biochemical interpretation of nanoparticle-related metabolic 
changes – aqueous extracts 
Several amino acids were found to vary in response to SNPs, in particular, BCAA, lysine, 
glycine, phenylalanine and tyrosine increased, whereas alanine, aspartate, glutamine, taurine 
and threonine decreased following SNPs exposure. BCAA are involved in stress, energy and 
muscle metabolism, being carefully regulated by an enzymatic system. They can undergo 
different metabolic routes, where valine goes to carbohydrates, leucine to fats and isoleucine 
to both. Therefore, they can be used for protein synthesis or to form a series of coenzyme A 
compounds that can be further oxidized for use in the TCA cycle in the forms of acetyl and 
succinyl CoA. In this work, the energy consumption and protein catabolism could be 
connected with BCAA increase and mobilization from proteins, but also with the increase 
of aromatic amino acids (tyrosine and phenylalanine) in response to SNPs exposure (59,86). 
Threonine can also lead to the formation of acetyl CoA and glycine, and its decrease could 
be an indicator of that conversion towards glycine, which was found to be increased. 
Glycine, usually involved in energy release and osmoregulation, is a precursor of reduced 
glutathione (GSH), an important anti-oxidant that has a key role in maintaining intracellular 
redox balance for the proper function of cellular proteins. Consistently, another indicator of 
de novo synthesis of GSH is the reduction of glutamine levels at the first 48h of SNPs 
exposure followed by an increase at the 72 hours. Another indicator is the high consumption 
of ATP along time, since GSH synthesis depends on ATP-driven enzymatic activity (87). 
These variations may reflect an adaptive response of RAW 264.7 cells to stress, avoiding 
oxidative damage (64,67). However, no relevant variations were found directly for GSH or 
GSSG. 
Another indirect regulator of oxidative stress is taurine, which improves mitochondrial 
function by diminishing superoxide generation. As previously described, the reduction in 
intracellular taurine levels causes a rise in oxidative stress, usually associated with a decrease 
in the integrity of the electron transport chain (88). Hence, the decreased levels of taurine 
induced by SNPs at an early stage indicated that SNPs lead to biochemical and physiological 
disturbances in many fundamental biological roles, such as anti-oxidation, osmoregulation 
and membrane stabilization (64,70). Also linked with oxidative phosphorylation in 
mitochondria is the decrease in ATP production, showing stress-related cellular response 
induced by SNPs. The reduced ATP levels along time suggests the increase of glycolysis 
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(77).  This is consistent with a significant increase in the levels of lactate coupled with the 
alteration in succinate and fumarate levels (TCA cycle intermediates), suggesting 
enhancement of the intracellular anaerobic glycolysis process. Thus, the reduced energy 
availability leads to an anaerobic metabolism. The glycolytic enzyme, lactate dehydrogenase 
A (LDHA), which catalyses the conversion between pyruvate and lactate plays an important 
role in generating lactate, that is expressively elevated (58,67). Alanine can also be converted 
to pyruvate and it decreased significantly. This perturbation in energy metabolism, 
accompanied by a decrease in pyruvate indicates a trend in metabolism towards the 
formation of acetyl CoA and/or lactate (71).  
Significant decreases were observed for NAD+, an important redox coenzyme involved 
in glycolysis and the TCA of cellular respiration. Depending on the cell metabolic strategy, 
this coenzyme is found either as an oxidizing (NAD+) or reducing agent (NADH), used in 
ATP production and modulating the cellular redox status (89).  
Creatine and phosphocreatine, two critical metabolites in the cell’s energy shuttle, are 
highly increased after the SNPs exposure. By reversible interconversion of creatine into 
phosphocreatine, creatine kinase is the responsible for metabolic regulation of energy fluxes 
and oxidative phosphorylation. Hence, changes in creatine kinase/phosphocreatine system 
suggest imbalance in cellular energy homeostasis (90).  
Myo-inositol, taurine and choline are metabolites involved is osmo-regulation, therefore 
their alterations may reflect changes is cellular osmotic balance in the presence of SNPs. 
(63,91). Moreover, choline and phosphocholine are breakdown products of 
phosphatidylcholine (PTC), a major cell membrane constituent. Their reduction may be 
reflective of cell membrane modification and/or proliferation arrest, as these metabolites are 
important constituents of membrane lipids (whose variations are discussed further ahead) 
(58,69).  
In summary, RAW 264.7 cells’ exposure to SNPs resulted in biochemical changes related 
to energy metabolism and TCA cycle, disturbance of amino acids metabolism and cell 
membrane modification, comparable to what was previously observed for macrophages 
exposed to USPIO (63) As already mentioned, macrophages are essential cells to recognize, 
phagocytose, and synthetize inflammatory mediators, being responsible for clearance and 
trafficking of NPs in vivo. Thus, monitoring macrophages metabolic response to 
nanoparticles potentially allows to understand the overall physiological response (92,93). In 
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this work, the metabolome of these cells was indeed found to vary significantly with cell 
growth and SNP exposure, providing important mechanistic leads on the cell-NP 
interactions. 
 
 
  
                                                                  Chapter 3 – Results and Discussion 
   62 
 
3.2.3. Effects on the macrophages’ lipidome assessed by 1H NMR spectroscopy 
of cellular lipid extracts 
In order to identify differences in the lipid composition of control cells and cells dosed 
with both low and high-concentration of SNPs, MVA was applied to the 1H NMR spectra of 
lipid extracts. As for the aqueous extracts, this analysis was conducted for each exposure 
period separately. The resulting PCA scores scatter plots are shown in Figure 23 (left). The 
clearest group separation is seen for the 48h-exposure, where high concentration SNP-
exposed samples are well separated from controls and low concentration SNP samples, these 
two being largely overlapped in the scores map. For the other time points, especially at 72h, 
group separation is not clear in PCA. Still, PLS-DA was performed for each time point, 
considering controls vs high concentration SNP-exposed samples. The corresponding PLS-
DA scores (Figure 23, right) show a clear separation between the two classes, with R2X ≥ 
0.5 and a high predictive power (Q2 ≥ 0.7).  
Figure 23 – Scores scatter plots obtained by PCA (left) and PLS-DA (right) of 1H NMR spectra from lipid 
extracts of control RAW 264.7 cells and cells exposed to SNPs for (A) 24 hours, (B) 48 hours and (C) 72 
hours. Circles, squares and triangles represent controls, low concentration and high concentration of SNPs, 
respectively. 
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Based on the inspection of LV1 loadings (Figure 24), the main lipid metabolites found to 
be responsible for the separation between controls and SNP-exposed cells were cholesterol, 
phosphatidylcholine, phosphatidylethanolamine, sphingomyelin and fatty acyl chains from 
phospholipids and triglycerides. The response profiles at  24 and 72 hours of exposure were 
quite similar, and characterised by increases in SM, cholesterol and cholesterol esters 
(negative loadings) and decreases in the fatty acyl chains of phospholipids (positive 
loadings) in relation to SNPs exposure. At 48 hours, the exposure to SNPs also led to the 
decrease of PTE, TG and plasmalogen, and PTC decreased contrarily to the first 24 hours of 
exposure. 
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Figure 24 – LV1 loadings w, coloured as a function of variable importance in the projection (VIP), 
corresponding to PLS-DA of 1H NMR spectra from lipid extracts of control RAW 264.7 cells and cells 
exposed to SNPs for (A) 24 hours, (B) 48 hours and (C) 72 hours. 
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The metabolic features discriminating controls and SNP-exposed cells were further 
inspected by spectral integration of the signals with higher VIP. Those showing statistically 
significant differences between controls and high concentration SNPs are listed in Table X 
along with the percentages of variation and effect sizes.  
 
Table X – Metabolite variations in lipid extracts of RAW 264.7 cells exposed to high 
concentration (500 µg/mL) of SNPs for 24, 48 and 72 hours, compared to control cells. (s, 
singlet; d, doublet; t, triplet; m, multiplet; dd, doublet of doublets). 
  Silk High 24H Silk High 48H Silk High 72H 
Metabolite (δ/ppm a, 
multiplicity) 
% Var. b d c % Var. b d c % Var. b d c 
Total Chol (s, 0.68) 132.45 ± 11.69 5.09 ± 2.40 38.50 ± 6.19 3.51 ± 1.79 25.29 ± 7.87 1.89 ± 1.34 
FA CH3(CH2)n  
(t, 0.88) 
-4.98 ± 0.76 -3.39 ± 1.81 -4.02 ± 1.36 -1.39 ± 1.24 -3.65 ± 1.56 -1.48 ± 1.26 
Free Chol (s, 1.01) 65.85 ± 9.28 3.61 ± 1.88 24.91 ± 5.93 2.56 ± 1.51 16.22 ± 7.31 1.46 ± 1.25 
Ester Chol (s, 1.02) 114.88 ± 14.43 4.00 ± 2.01 36.06 ± 6.83 2.39 ± 1.46 37.30 ± 8.33 2.14 ± 1.40 
FA (CH2)n (m, 1.25) 6.70 ± 3.68 - - - - - 
FA (-CH2CH=)  
(m, 2.00) 
-19.34 ± 10.21 - - - -10.26 ± 3.20 -1.79 ± 1.32 
FA (=CHCH2CH=) 
(m,2.83) 
8.77 ± 5.96 - -16.55 ± 4.62 -1.62 ± 1.28 -17.16 ± 5.52 -1.68 ± 1.30 
FA (-HC=CH-) 
(m, 5.35) 
-19.76 ± 9.12 - - - -12.24 ± 4.01 -1.65 ± 1.29 
Plasmalogen (5.91) - - -35.25 ± 7.51 -2.46 ± 1.48 -28.80 ± 5.49 -2.88 ± 1.60 
PTC (s, 3.35) 45.15 ± 13.53 1.58 ± 1.30 -32.75 ± 22.67 -1.27 ± 1.22 -16.15 ± 5.71 -1.50 ± 1.26 
SM (s, 3.35) 372.19 ± 125.38 - 163.23 ± 21.27 2.49 ± 1.49 65.66 ± 22.42 1.26 ± 1.22 
a Resonance chosen for signal integration. b % Variation. c d – Effect size in relation to control cells. -, no 
significant variation. 
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A heatmap representation of the effect size of lipid variations, in exposed cells relatively 
to controls, is shown in Figure 25. 
Cholesterol, cholesterol esters and SM were found to be relatively higher in SNP- exposed 
samples, whereas FA, plasmalogen and PTC were higher in controls. Interestingly, 
cholesterol, SM and PTC are components of cell membranes but behave differently along 
time. These variations are probably associated with cell membrane modification of 
macrophages, occurring at a later stage (48 hours). 
 
3.2.3.1. Proposed biochemical interpretation of nanoparticle-related metabolic 
changes – lipid extracts 
Lipids have a central role in mammalian cell function, comprising major structural and 
metabolic components of cells. Lipid metabolism contributes to fulfil energetic needs and 
membrane fluidity of the cells. This process is very important during macrophage activation 
and phagocytosis in response to external stimuli, such as nanoparticles’ exposure. Also, the 
ratio of saturated and unsaturated fatty acids can, indeed, modulate macrophage 
phagocytosis. Therefore, macrophages are capable of alter their lipid profile and produce 
lipid mediator accordingly to the cell’s needs (85,93).  
The main changes identified upon SNPs exposure were global increases in cholesterol, 
cholesterol esters and sphingomyelin, whereas unsaturated fatty acids, plasmalogen and 
phosphatidylcholine were higher in controls. These changes may reflect variations in 
Figure 25 – Heatmap of effect size values of the main lipid metabolite variations in SNPs-exposed cells 
(low concentration 10 µg/mL; high concentration 500 µg/mL), at different exposure periods (24, 48 and 72 
hours). The colour scale reflects the direction and magnitude of these variations in exposed cells relative to 
control cells (collected for each respective time point). * p < 0.05; ** p < 0.01. (Chol cholesterol; FA Fatty 
acyl chains; PTC phosphatidylcholine; SM sphingomyelin). 
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membrane composition and fluidity, similarly to what has been reported for macrophages 
exposed to silver nanoparticles (94). Moreover, the elevation in cholesterol and 
sphingomyelin might reflect regulatory cross-talk between cholesterol and sphingolipid 
metabolism (85). Interestingly, some of these differences were time-dependent, with higher 
impact at the 48 hours exposure. This may indicate that the first 48 hours were an important 
period for the phagocytic activity of SNPs by macrophages. As described by Haase’s team, 
the functionality of phagocytic activity is connected with cell membrane integrity (94). 
Following the 72h time point, metabolites variations seem to stabilize, suggesting some 
cellular metabolic recovery. 
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In this work, the metabolic composition of RAW 264.7 cells was characterized by 1D and 
2D NMR spectroscopy, which allowed us to establish a database of metabolites for murine 
macrophages. In the aqueous extract, almost forty metabolites were unambiguously 
identified, including amino acids, organic acids, choline-containing compounds and 
nucleotides. Regarding the lipid composition, the assignment of the main lipid classes 
included cholesterol and cholesterol esters, phosphatidylcholine, phosphatidylethanolamine, 
sphingomyelin, plasmalogen and fatty acids. Interestingly, the cells metabolome and 
lipidome were found to change with culture time, reflecting metabolic adaptations during 
normal cell growth. 
The assessment of the compositional changes in macrophages during silk nanoparticles’ 
exposure was also performed. Multivariate analysis was carried out on the NMR spectra, 
revealing that silk nanoparticles impacted cell metabolism in a time and concentration-
dependent manner. While some variations were common to all exposure periods, such as the 
increase in branched chain amino acids, lactate and tyrosine or the decrease in glutamine, 
taurine, myo-inositol and ATP/ADP, others seemed to be more time-specific. In regard to 
lipids, cholesterol, cholesterol esters and sphingomyelin were found to be relatively higher 
in SNP-exposed samples, whereas fatty acids, plasmalogen and phosphatidylcholine were 
higher in controls.  
In summary, RAW 264.7 cells’ exposure to silk nanoparticles entailed prominent 
biochemical changes in cell metabolism, suggesting downregulated TCA cycle activity, 
energy depletion, disturbance of amino acids metabolism and cell membrane modification.  
Particularly, whereas no metabolic changes were observed with the lowest concentration 
of silk nanoparticles, with cell viability above 70 %, at a higher concentration of SNPs, those 
changes were clear. Using a high concentration of SNPs, numerous changes were detected 
and, although cell viability reached a lower value than the IC50 for the 72h period, at the 
first 48h cell viability remained above 60%. This is a reflex of the ability of macrophages to 
adapt and reprogram their function in response to compositional changes relatively to growth 
needs and SNPs-exposure. 
A thorough understanding of nanomedicines biological effects will allow an optimization 
of their rationale design and safety profiles, from early development stages. Metabolic 
profiling offers a window into the impact of external stimuli (such as a nanomaterial) on 
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cellular metabolism. Therefore, it has the potential to reveal response markers of efficacy or 
toxicity, as well as provide biochemical insight into mechanisms of action. 
In the future, the confirmation of these results could be accomplished with more sensitive 
techniques such as mass spectrometry, for instance to analyse lipid composition in more 
detail, and through the measurement of the expression/activity of specific enzymes to follow 
the fate of selected substrates. Moreover, the assessment of the metabolic alterations of RAW 
264.7 cells found to be associated with SNPs, should be compared with other cell type’s 
responses. Also, studies involving surface-modified and/or drug-loaded SNPs should also 
be performed to evaluate the ability of silk of acting as a drug delivery system. 
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